Risk of second primary malignancies following radioactive iodine therapy in thyroid cancer: A meta-analysis of 1,189,992 patients

Risk of second primary malignancies following... | F1000Research "use strict";function _typeof(t){return(_typeof="function"==typeof Symbol&&"symbol"==typeof Symbol.iterator?function(t){return typeof t}:function(t){return t&&"function"==typeof Symbol&&t.constructor===Symbol&&t!==Symbol.prototype?"symbol":typeof t})(t)}!function(){var t=function(){var t,e,o=[],n=window,r=n;for(;r;){try{if(r.frames.__tcfapiLocator){t=r;break}}catch(t){}if(r===n.top)break;r=r.parent}t||(!function t(){var e=n.document,o=!!n.frames.__tcfapiLocator;if(!o)if(e.body){var r=e.createElement("iframe");r.style.cssText="display:none",r.name="__tcfapiLocator",e.body.appendChild(r)}else setTimeout(t,5);return!o}(),n.__tcfapi=function(){for(var t=arguments.length,n=new Array(t),r=0;r 3&&2===parseInt(n[1],10)&&"boolean"==typeof n[3]&&(e=n[3],"function"==typeof n[2]&&n[2]("set",!0)):"ping"===n[0]?"function"==typeof n[2]&&n[2]({gdprApplies:e,cmpLoaded:!1,cmpStatus:"stub"}):o.push(n)},n.addEventListener("message",(function(t){var e="string"==typeof t.data,o={};if(e)try{o=JSON.parse(t.data)}catch(t){}else o=t.data;var n="object"===_typeof(o)&&null!==o?o.__tcfapiCall:null;n&&window.__tcfapi(n.command,n.version,(function(o,r){var a={__tcfapiReturn:{returnValue:o,success:r,callId:n.callId}};t&&t.source&&t.source.postMessage&&t.source.postMessage(e?JSON.stringify(a):a,"*")}),n.parameter)}),!1))};"undefined"!=typeof module?module.exports=t:t()}(); dataLayer = dataLayer || []; // Standard GTM initialization - Google Consent Mode handles consent automatically (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl+ '>m_auth=hzk0Vc3qFsQYhCrIoHz68A>m_preview=env-1>m_cookies_win=x';f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-MWFK8L5J'); ;window.NREUM||(NREUM={});NREUM.init={distributed_tracing:{enabled:true},privacy:{cookies_enabled:true},ajax:{deny_list:["bam.nr-data.net"]}}; ;NREUM.loader_config={accountID:"438030",trustKey:"438030",agentID:"772317073",licenseKey:"97f8f67f26",applicationID:"772317073"} ;NREUM.info={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",licenseKey:"97f8f67f26",applicationID:"772317073",sa:1} ;/*! For license information please see nr-loader-spa-1.236.0.min.js.LICENSE.txt */ (()=>{"use strict";var e,t,r={5763:(e,t,r)=>{r.d(t,{P_:()=>l,Mt:()=>g,C5:()=>s,DL:()=>v,OP:()=>T,lF:()=>D,Yu:()=>y,Dg:()=>h,CX:()=>c,GE:()=>b,sU:()=>_});var n=r(8632),i=r(9567);const o={beacon:n.ce.beacon,errorBeacon:n.ce.errorBeacon,licenseKey:void 0,applicationID:void 0,sa:void 0,queueTime:void 0,applicationTime:void 0,ttGuid:void 0,user:void 0,account:void 0,product:void 0,extra:void 0,jsAttributes:{},userAttributes:void 0,atts:void 0,transactionName:void 0,tNamePlain:void 0},a={};function s(e){if(!e)throw new Error("All info objects require an agent identifier!");if(!a[e])throw new Error("Info for ".concat(e," was never set"));return a[e]}function c(e,t){if(!e)throw new Error("All info objects require an agent identifier!");a[e]=(0,i.D)(t,o),(0,n.Qy)(e,a[e],"info")}var u=r(7056);const d=()=>{const e={blockSelector:"[data-nr-block]",maskInputOptions:{password:!0}};return{allow_bfcache:!0,privacy:{cookies_enabled:!0},ajax:{deny_list:void 0,enabled:!0,harvestTimeSeconds:10},distributed_tracing:{enabled:void 0,exclude_newrelic_header:void 0,cors_use_newrelic_header:void 0,cors_use_tracecontext_headers:void 0,allowed_origins:void 0},session:{domain:void 0,expiresMs:u.oD,inactiveMs:u.Hb},ssl:void 0,obfuscate:void 0,jserrors:{enabled:!0,harvestTimeSeconds:10},metrics:{enabled:!0},page_action:{enabled:!0,harvestTimeSeconds:30},page_view_event:{enabled:!0},page_view_timing:{enabled:!0,harvestTimeSeconds:30,long_task:!1},session_trace:{enabled:!0,harvestTimeSeconds:10},harvest:{tooManyRequestsDelay:60},session_replay:{enabled:!1,harvestTimeSeconds:60,sampleRate:.1,errorSampleRate:.1,maskTextSelector:"*",maskAllInputs:!0,get blockClass(){return"nr-block"},get ignoreClass(){return"nr-ignore"},get maskTextClass(){return"nr-mask"},get blockSelector(){return e.blockSelector},set blockSelector(t){e.blockSelector+=",".concat(t)},get maskInputOptions(){return e.maskInputOptions},set maskInputOptions(t){e.maskInputOptions={...t,password:!0}}},spa:{enabled:!0,harvestTimeSeconds:10}}},f={};function l(e){if(!e)throw new Error("All configuration objects require an agent identifier!");if(!f[e])throw new Error("Configuration for ".concat(e," was never set"));return f[e]}function h(e,t){if(!e)throw new Error("All configuration objects require an agent identifier!");f[e]=(0,i.D)(t,d()),(0,n.Qy)(e,f[e],"config")}function g(e,t){if(!e)throw new Error("All configuration objects require an agent identifier!");var r=l(e);if(r){for(var n=t.split("."),i=0;i {r.d(t,{D:()=>i});var n=r(50);function i(e,t){try{if(!e||"object"!=typeof e)return(0,n.Z)("Setting a Configurable requires an object as input");if(!t||"object"!=typeof t)return(0,n.Z)("Setting a Configurable requires a model to set its initial properties");const r=Object.create(Object.getPrototypeOf(t),Object.getOwnPropertyDescriptors(t)),o=0===Object.keys(r).length?e:r;for(let a in o)if(void 0!==e[a])try{"object"==typeof e[a]&&"object"==typeof t[a]?r[a]=i(e[a],t[a]):r[a]=e[a]}catch(e){(0,n.Z)("An error occurred while setting a property of a Configurable",e)}return r}catch(e){(0,n.Z)("An error occured while setting a Configurable",e)}}},6818:(e,t,r)=>{r.d(t,{Re:()=>i,gF:()=>o,q4:()=>n});const n="1.236.0",i="PROD",o="CDN"},385:(e,t,r)=>{r.d(t,{FN:()=>a,IF:()=>u,Nk:()=>f,Tt:()=>s,_A:()=>o,il:()=>n,pL:()=>c,v6:()=>i,w1:()=>d});const n="undefined"!=typeof window&&!!window.document,i="undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self.navigator instanceof WorkerNavigator||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis.navigator instanceof WorkerNavigator),o=n?window:"undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis),a=""+o?.location,s=/iPad|iPhone|iPod/.test(navigator.userAgent),c=s&&"undefined"==typeof SharedWorker,u=(()=>{const e=navigator.userAgent.match(/Firefox[/\s](\d+\.\d+)/);return Array.isArray(e)&&e.length>=2?+e[1]:0})(),d=Boolean(n&&window.document.documentMode),f=!!navigator.sendBeacon},1117:(e,t,r)=>{r.d(t,{w:()=>o});var n=r(50);const i={agentIdentifier:"",ee:void 0};class o{constructor(e){try{if("object"!=typeof e)return(0,n.Z)("shared context requires an object as input");this.sharedContext={},Object.assign(this.sharedContext,i),Object.entries(e).forEach((e=>{let[t,r]=e;Object.keys(i).includes(t)&&(this.sharedContext[t]=r)}))}catch(e){(0,n.Z)("An error occured while setting SharedContext",e)}}}},8e3:(e,t,r)=>{r.d(t,{L:()=>d,R:()=>c});var n=r(2177),i=r(1284),o=r(4322),a=r(3325);const s={};function c(e,t){const r={staged:!1,priority:a.p[t]||0};u(e),s[e].get(t)||s[e].set(t,r)}function u(e){e&&(s[e]||(s[e]=new Map))}function d(){let e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:"",t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:"feature";if(u(e),!e||!s[e].get(t))return a(t);s[e].get(t).staged=!0;const r=[...s[e]];function a(t){const r=e?n.ee.get(e):n.ee,a=o.X.handlers;if(r.backlog&&a){var s=r.backlog[t],c=a[t];if(c){for(var u=0;s&&u {let[t,r]=e;return r.staged}))&&(r.sort(((e,t)=>e[1].priority-t[1].priority)),r.forEach((e=>{let[t]=e;a(t)})))}function f(e,t){var r=e[1];(0,i.D)(t[r],(function(t,r){var n=e[0];if(r[0]===n){var i=r[1],o=e[3],a=e[2];i.apply(o,a)}}))}},2177:(e,t,r)=>{r.d(t,{c:()=>f,ee:()=>u});var n=r(8632),i=r(2210),o=r(1284),a=r(5763),s="nr@context";let c=(0,n.fP)();var u;function d(){}function f(e){return(0,i.X)(e,s,l)}function l(){return new d}function h(){u.aborted=!0,u.backlog={}}c.ee?u=c.ee:(u=function e(t,r){var n={},c={},f={},g=!1;try{g=16===r.length&&(0,a.OP)(r).isolatedBacklog}catch(e){}var p={on:b,addEventListener:b,removeEventListener:y,emit:v,get:x,listeners:w,context:m,buffer:A,abort:h,aborted:!1,isBuffering:E,debugId:r,backlog:g?{}:t&&"object"==typeof t.backlog?t.backlog:{}};return p;function m(e){return e&&e instanceof d?e:e?(0,i.X)(e,s,l):l()}function v(e,r,n,i,o){if(!1!==o&&(o=!0),!u.aborted||i){t&&o&&t.emit(e,r,n);for(var a=m(n),s=w(e),d=s.length,f=0;fn,p:()=>i});var n=r(2177).ee.get("handle");function i(e,t,r,i,o){o?(o.buffer([e],i),o.emit(e,t,r)):(n.buffer([e],i),n.emit(e,t,r))}},4322:(e,t,r)=>{r.d(t,{X:()=>o});var n=r(5546);o.on=a;var i=o.handlers={};function o(e,t,r,o){a(o||n.E,i,e,t,r)}function a(e,t,r,i,o){o||(o="feature"),e||(e=n.E);var a=t[o]=t[o]||{};(a[r]=a[r]||[]).push([e,i])}},3239:(e,t,r)=>{r.d(t,{bP:()=>s,iz:()=>c,m$:()=>a});var n=r(385);let i=!1,o=!1;try{const e={get passive(){return i=!0,!1},get signal(){return o=!0,!1}};n._A.addEventListener("test",null,e),n._A.removeEventListener("test",null,e)}catch(e){}function a(e,t){return i||o?{capture:!!e,passive:i,signal:t}:!!e}function s(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=arguments.length>3?arguments[3]:void 0;window.addEventListener(e,t,a(r,n))}function c(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=arguments.length>3?arguments[3]:void 0;document.addEventListener(e,t,a(r,n))}},4402:(e,t,r)=>{r.d(t,{Ht:()=>u,M:()=>c,Rl:()=>a,ky:()=>s});var n=r(385);const i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx";function o(e,t){return e?15&e[t]:16*Math.random()|0}function a(){const e=n._A?.crypto||n._A?.msCrypto;let t,r=0;return e&&e.getRandomValues&&(t=e.getRandomValues(new Uint8Array(31))),i.split("").map((e=>"x"===e?o(t,++r).toString(16):"y"===e?(3&o()|8).toString(16):e)).join("")}function s(e){const t=n._A?.crypto||n._A?.msCrypto;let r,i=0;t&&t.getRandomValues&&(r=t.getRandomValues(new Uint8Array(31)));const a=[];for(var s=0;s {r.d(t,{Bq:()=>n,Hb:()=>o,oD:()=>i});const n="NRBA",i=144e5,o=18e5},7894:(e,t,r)=>{function n(){return Math.round(performance.now())}r.d(t,{z:()=>n})},7243:(e,t,r)=>{r.d(t,{e:()=>o});var n=r(385),i={};function o(e){if(e in i)return i[e];if(0===(e||"").indexOf("data:"))return{protocol:"data"};let t;var r=n._A?.location,o={};if(n.il)t=document.createElement("a"),t.href=e;else try{t=new URL(e,r.href)}catch(e){return o}o.port=t.port;var a=t.href.split("://");!o.port&&a[1]&&(o.port=a[1].split("/")[0].split("@").pop().split(":")[1]),o.port&&"0"!==o.port||(o.port="https"===a[0]?"443":"80"),o.hostname=t.hostname||r.hostname,o.pathname=t.pathname,o.protocol=a[0],"/"!==o.pathname.charAt(0)&&(o.pathname="/"+o.pathname);var s=!t.protocol||":"===t.protocol||t.protocol===r.protocol,c=t.hostname===r.hostname&&t.port===r.port;return o.sameOrigin=s&&(!t.hostname||c),"/"===o.pathname&&(i[e]=o),o}},50:(e,t,r)=>{function n(e,t){"function"==typeof console.warn&&(console.warn("New Relic: ".concat(e)),t&&console.warn(t))}r.d(t,{Z:()=>n})},2587:(e,t,r)=>{r.d(t,{N:()=>c,T:()=>u});var n=r(2177),i=r(5546),o=r(8e3),a=r(3325);const s={stn:[a.D.sessionTrace],err:[a.D.jserrors,a.D.metrics],ins:[a.D.pageAction],spa:[a.D.spa],sr:[a.D.sessionReplay,a.D.sessionTrace]};function c(e,t){const r=n.ee.get(t);e&&"object"==typeof e&&(Object.entries(e).forEach((e=>{let[t,n]=e;void 0===u[t]&&(s[t]?s[t].forEach((e=>{n?(0,i.p)("feat-"+t,[],void 0,e,r):(0,i.p)("block-"+t,[],void 0,e,r),(0,i.p)("rumresp-"+t,[Boolean(n)],void 0,e,r)})):n&&(0,i.p)("feat-"+t,[],void 0,void 0,r),u[t]=Boolean(n))})),Object.keys(s).forEach((e=>{void 0===u[e]&&(s[e]?.forEach((t=>(0,i.p)("rumresp-"+e,[!1],void 0,t,r))),u[e]=!1)})),(0,o.L)(t,a.D.pageViewEvent))}const u={}},2210:(e,t,r)=>{r.d(t,{X:()=>i});var n=Object.prototype.hasOwnProperty;function i(e,t,r){if(n.call(e,t))return e[t];var i=r();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,t,{value:i,writable:!0,enumerable:!1}),i}catch(e){}return e[t]=i,i}},1284:(e,t,r)=>{r.d(t,{D:()=>n});const n=(e,t)=>Object.entries(e||{}).map((e=>{let[r,n]=e;return t(r,n)}))},4351:(e,t,r)=>{r.d(t,{P:()=>o});var n=r(2177);const i=()=>{const e=new WeakSet;return(t,r)=>{if("object"==typeof r&&null!==r){if(e.has(r))return;e.add(r)}return r}};function o(e){try{return JSON.stringify(e,i())}catch(e){try{n.ee.emit("internal-error",[e])}catch(e){}}}},3960:(e,t,r)=>{r.d(t,{K:()=>a,b:()=>o});var n=r(3239);function i(){return"undefined"==typeof document||"complete"===document.readyState}function o(e,t){if(i())return e();(0,n.bP)("load",e,t)}function a(e){if(i())return e();(0,n.iz)("DOMContentLoaded",e)}},8632:(e,t,r)=>{r.d(t,{EZ:()=>u,Qy:()=>c,ce:()=>o,fP:()=>a,gG:()=>d,mF:()=>s});var n=r(7894),i=r(385);const o={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net"};function a(){return i._A.NREUM||(i._A.NREUM={}),void 0===i._A.newrelic&&(i._A.newrelic=i._A.NREUM),i._A.NREUM}function s(){let e=a();return e.o||(e.o={ST:i._A.setTimeout,SI:i._A.setImmediate,CT:i._A.clearTimeout,XHR:i._A.XMLHttpRequest,REQ:i._A.Request,EV:i._A.Event,PR:i._A.Promise,MO:i._A.MutationObserver,FETCH:i._A.fetch}),e}function c(e,t,r){let i=a();const o=i.initializedAgents||{},s=o[e]||{};return Object.keys(s).length||(s.initializedAt={ms:(0,n.z)(),date:new Date}),i.initializedAgents={...o,[e]:{...s,[r]:t}},i}function u(e,t){a()[e]=t}function d(){return function(){let e=a();const t=e.info||{};e.info={beacon:o.beacon,errorBeacon:o.errorBeacon,...t}}(),function(){let e=a();const t=e.init||{};e.init={...t}}(),s(),function(){let e=a();const t=e.loader_config||{};e.loader_config={...t}}(),a()}},7956:(e,t,r)=>{r.d(t,{N:()=>i});var n=r(3239);function i(e){let t=arguments.length>1&&void 0!==arguments[1]&&arguments[1],r=arguments.length>2?arguments[2]:void 0,i=arguments.length>3?arguments[3]:void 0;return void(0,n.iz)("visibilitychange",(function(){if(t)return void("hidden"==document.visibilityState&&e());e(document.visibilityState)}),r,i)}},1214:(e,t,r)=>{r.d(t,{em:()=>v,u5:()=>N,QU:()=>S,_L:()=>I,Gm:()=>L,Lg:()=>M,gy:()=>U,BV:()=>Q,Kf:()=>ee});var n=r(2177);const i="nr@original";var o=Object.prototype.hasOwnProperty,a=!1;function s(e,t){return e||(e=n.ee),r.inPlace=function(e,t,n,i,o){n||(n="");var a,s,c,u="-"===n.charAt(0);for(c=0;c 2?n-2:0),o=2;o {r(A[T],e,w),r(E[T],e,w)})),r(l._A,"fetch",y),t.on(y+"end",(function(e,r){var n=this;if(r){var i=r.headers.get("content-length");null!==i&&(n.rxSize=i),t.emit(y+"done",[null,r],n)}else t.emit(y+"done",[e],n)})),t}const O={},j=["pushState","replaceState"];function S(e){const t=function(e){return(e||n.ee).get("history")}(e);return!l.il||O[t.debugId]++||(O[t.debugId]=1,s(t).inPlace(window.history,j,"-")),t}var P=r(3239);const C={},R=["appendChild","insertBefore","replaceChild"];function I(e){const t=function(e){return(e||n.ee).get("jsonp")}(e);if(!l.il||C[t.debugId])return t;C[t.debugId]=!0;var r=s(t),i=/[?&](?:callback|cb)=([^&#]+)/,o=/(.*)\.([^.]+)/,a=/^(\w+)(\.|$)(.*)$/;function c(e,t){var r=e.match(a),n=r[1],i=r[3];return i?c(i,t[n]):t[n]}return r.inPlace(Node.prototype,R,"dom-"),t.on("dom-start",(function(e){!function(e){if(!e||"string"!=typeof e.nodeName||"script"!==e.nodeName.toLowerCase())return;if("function"!=typeof e.addEventListener)return;var n=(a=e.src,s=a.match(i),s?s[1]:null);var a,s;if(!n)return;var u=function(e){var t=e.match(o);if(t&&t.length>=3)return{key:t[2],parent:c(t[1],window)};return{key:e,parent:window}}(n);if("function"!=typeof u.parent[u.key])return;var d={};function f(){t.emit("jsonp-end",[],d),e.removeEventListener("load",f,(0,P.m$)(!1)),e.removeEventListener("error",l,(0,P.m$)(!1))}function l(){t.emit("jsonp-error",[],d),t.emit("jsonp-end",[],d),e.removeEventListener("load",f,(0,P.m$)(!1)),e.removeEventListener("error",l,(0,P.m$)(!1))}r.inPlace(u.parent,[u.key],"cb-",d),e.addEventListener("load",f,(0,P.m$)(!1)),e.addEventListener("error",l,(0,P.m$)(!1)),t.emit("new-jsonp",[e.src],d)}(e[0])})),t}var k=r(5763);const H={};function L(e){const t=function(e){return(e||n.ee).get("mutation")}(e);if(!l.il||H[t.debugId])return t;H[t.debugId]=!0;var r=s(t),i=k.Yu.MO;return i&&(window.MutationObserver=function(e){return this instanceof i?new i(r(e,"fn-")):i.apply(this,arguments)},MutationObserver.prototype=i.prototype),t}const z={};function M(e){const t=function(e){return(e||n.ee).get("promise")}(e);if(z[t.debugId])return t;z[t.debugId]=!0;var r=n.c,o=s(t),a=k.Yu.PR;return a&&function(){function e(r){var n=t.context(),i=o(r,"executor-",n,null,!1);const s=Reflect.construct(a,[i],e);return t.context(s).getCtx=function(){return n},s}l._A.Promise=e,Object.defineProperty(e,"name",{value:"Promise"}),e.toString=function(){return a.toString()},Object.setPrototypeOf(e,a),["all","race"].forEach((function(r){const n=a[r];e[r]=function(e){let i=!1;[...e||[]].forEach((e=>{this.resolve(e).then(a("all"===r),a(!1))}));const o=n.apply(this,arguments);return o;function a(e){return function(){t.emit("propagate",[null,!i],o,!1,!1),i=i||!e}}}})),["resolve","reject"].forEach((function(r){const n=a[r];e[r]=function(e){const r=n.apply(this,arguments);return e!==r&&t.emit("propagate",[e,!0],r,!1,!1),r}})),e.prototype=a.prototype;const n=a.prototype.then;a.prototype.then=function(){var e=this,i=r(e);i.promise=e;for(var a=arguments.length,s=new Array(a),c=0;c e())),t};function m(e,t){i.inPlace(t,["onreadystatechange"],"fn-",E)}function b(){var e=this,t=r.context(e);e.readyState>3&&!t.resolved&&(t.resolved=!0,r.emit("xhr-resolved",[],e)),i.inPlace(e,f,"fn-",E)}if(function(e,t){for(var r in e)t[r]=e[r]}(o,p),p.prototype=o.prototype,i.inPlace(p.prototype,J,"-xhr-",E),r.on("send-xhr-start",(function(e,t){m(e,t),function(e){h.push(e),a&&(y?y.then(A):u?u(A):(w=-w,x.data=w))}(t)})),r.on("open-xhr-start",m),a){var y=c&&c.resolve();if(!u&&!c){var w=1,x=document.createTextNode(w);new a(A).observe(x,{characterData:!0})}}else t.on("fn-end",(function(e){e[0]&&e[0].type===d||A()}));function A(){for(var e=0;e {r.d(t,{t:()=>n});const n=r(3325).D.ajax},6660:(e,t,r)=>{r.d(t,{A:()=>i,t:()=>n});const n=r(3325).D.jserrors,i="nr@seenError"},3081:(e,t,r)=>{r.d(t,{gF:()=>o,mY:()=>i,t9:()=>n,vz:()=>s,xS:()=>a});const n=r(3325).D.metrics,i="sm",o="cm",a="storeSupportabilityMetrics",s="storeEventMetrics"},4649:(e,t,r)=>{r.d(t,{t:()=>n});const n=r(3325).D.pageAction},7633:(e,t,r)=>{r.d(t,{Dz:()=>i,OJ:()=>a,qw:()=>o,t9:()=>n});const n=r(3325).D.pageViewEvent,i="firstbyte",o="domcontent",a="windowload"},9251:(e,t,r)=>{r.d(t,{t:()=>n});const n=r(3325).D.pageViewTiming},3614:(e,t,r)=>{r.d(t,{BST_RESOURCE:()=>i,END:()=>s,FEATURE_NAME:()=>n,FN_END:()=>u,FN_START:()=>c,PUSH_STATE:()=>d,RESOURCE:()=>o,START:()=>a});const n=r(3325).D.sessionTrace,i="bstResource",o="resource",a="-start",s="-end",c="fn"+a,u="fn"+s,d="pushState"},7836:(e,t,r)=>{r.d(t,{BODY:()=>A,CB_END:()=>E,CB_START:()=>u,END:()=>x,FEATURE_NAME:()=>i,FETCH:()=>_,FETCH_BODY:()=>v,FETCH_DONE:()=>m,FETCH_START:()=>p,FN_END:()=>c,FN_START:()=>s,INTERACTION:()=>l,INTERACTION_API:()=>d,INTERACTION_EVENTS:()=>o,JSONP_END:()=>b,JSONP_NODE:()=>g,JS_TIME:()=>T,MAX_TIMER_BUDGET:()=>a,REMAINING:()=>f,SPA_NODE:()=>h,START:()=>w,originalSetTimeout:()=>y});var n=r(5763);const i=r(3325).D.spa,o=["click","submit","keypress","keydown","keyup","change"],a=999,s="fn-start",c="fn-end",u="cb-start",d="api-ixn-",f="remaining",l="interaction",h="spaNode",g="jsonpNode",p="fetch-start",m="fetch-done",v="fetch-body-",b="jsonp-end",y=n.Yu.ST,w="-start",x="-end",A="-body",E="cb"+x,T="jsTime",_="fetch"},5938:(e,t,r)=>{r.d(t,{W:()=>o});var n=r(5763),i=r(2177);class o{constructor(e,t,r){this.agentIdentifier=e,this.aggregator=t,this.ee=i.ee.get(e,(0,n.OP)(this.agentIdentifier).isolatedBacklog),this.featureName=r,this.blocked=!1}}},9144:(e,t,r)=>{r.d(t,{j:()=>m});var n=r(3325),i=r(5763),o=r(5546),a=r(2177),s=r(7894),c=r(8e3),u=r(3960),d=r(385),f=r(50),l=r(3081),h=r(8632);function g(){const e=(0,h.gG)();["setErrorHandler","finished","addToTrace","inlineHit","addRelease","addPageAction","setCurrentRouteName","setPageViewName","setCustomAttribute","interaction","noticeError","setUserId"].forEach((t=>{e[t]=function(){for(var r=arguments.length,n=new Array(r),i=0;i 1?r-1:0),i=1;i {e.exposed&&e.api[t]&&o.push(e.api[t](...n))})),o.length>1?o:o[0]}(t,...n)}}))}var p=r(2587);function m(e){let t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},m=arguments.length>2?arguments[2]:void 0,v=arguments.length>3?arguments[3]:void 0,{init:b,info:y,loader_config:w,runtime:x={loaderType:m},exposed:A=!0}=t;const E=(0,h.gG)();y||(b=E.init,y=E.info,w=E.loader_config),(0,i.Dg)(e,b||{}),(0,i.GE)(e,w||{}),(0,i.sU)(e,x),y.jsAttributes??={},d.v6&&(y.jsAttributes.isWorker=!0),(0,i.CX)(e,y),g();const T=function(e,t){t||(0,c.R)(e,"api");const h={};var g=a.ee.get(e),p=g.get("tracer"),m="api-",v=m+"ixn-";function b(t,r,n,o){const a=(0,i.C5)(e);return null===r?delete a.jsAttributes[t]:(0,i.CX)(e,{...a,jsAttributes:{...a.jsAttributes,[t]:r}}),x(m,n,!0,o||null===r?"session":void 0)(t,r)}function y(){}["setErrorHandler","finished","addToTrace","inlineHit","addRelease"].forEach((e=>h[e]=x(m,e,!0,"api"))),h.addPageAction=x(m,"addPageAction",!0,n.D.pageAction),h.setCurrentRouteName=x(m,"routeName",!0,n.D.spa),h.setPageViewName=function(t,r){if("string"==typeof t)return"/"!==t.charAt(0)&&(t="/"+t),(0,i.OP)(e).customTransaction=(r||"http://custom.transaction")+t,x(m,"setPageViewName",!0)()},h.setCustomAttribute=function(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2];if("string"==typeof e){if(["string","number"].includes(typeof t)||null===t)return b(e,t,"setCustomAttribute",r);(0,f.Z)("Failed to execute setCustomAttribute.\nNon-null value must be a string or number type, but a type of was provided."))}else(0,f.Z)("Failed to execute setCustomAttribute.\nName must be a string type, but a type of was provided."))},h.setUserId=function(e){if("string"==typeof e||null===e)return b("enduser.id",e,"setUserId",!0);(0,f.Z)("Failed to execute setUserId.\nNon-null value must be a string type, but a type of was provided."))},h.interaction=function(){return(new y).get()};var w=y.prototype={createTracer:function(e,t){var r={},i=this,a="function"==typeof t;return(0,o.p)(v+"tracer",[(0,s.z)(),e,r],i,n.D.spa,g),function(){if(p.emit((a?"":"no-")+"fn-start",[(0,s.z)(),i,a],r),a)try{return t.apply(this,arguments)}catch(e){throw p.emit("fn-err",[arguments,this,"string"==typeof e?new Error(e):e],r),e}finally{p.emit("fn-end",[(0,s.z)()],r)}}}};function x(e,t,r,i){return function(){return(0,o.p)(l.xS,["API/"+t+"/called"],void 0,n.D.metrics,g),i&&(0,o.p)(e+t,[(0,s.z)(),...arguments],r?null:this,i,g),r?void 0:this}}function A(){r.e(439).then(r.bind(r,7438)).then((t=>{let{setAPI:r}=t;r(e),(0,c.L)(e,"api")})).catch((()=>(0,f.Z)("Downloading runtime APIs failed...")))}return["actionText","setName","setAttribute","save","ignore","onEnd","getContext","end","get"].forEach((e=>{w[e]=x(v,e,void 0,n.D.spa)})),h.noticeError=function(e,t){"string"==typeof e&&(e=new Error(e)),(0,o.p)(l.xS,["API/noticeError/called"],void 0,n.D.metrics,g),(0,o.p)("err",[e,(0,s.z)(),!1,t],void 0,n.D.jserrors,g)},d.il?(0,u.b)((()=>A()),!0):A(),h}(e,v);return(0,h.Qy)(e,T,"api"),(0,h.Qy)(e,A,"exposed"),(0,h.EZ)("activatedFeatures",p.T),T}},3325:(e,t,r)=>{r.d(t,{D:()=>n,p:()=>i});const n={ajax:"ajax",jserrors:"jserrors",metrics:"metrics",pageAction:"page_action",pageViewEvent:"page_view_event",pageViewTiming:"page_view_timing",sessionReplay:"session_replay",sessionTrace:"session_trace",spa:"spa"},i={[n.pageViewEvent]:1,[n.pageViewTiming]:2,[n.metrics]:3,[n.jserrors]:4,[n.ajax]:5,[n.sessionTrace]:6,[n.pageAction]:7,[n.spa]:8,[n.sessionReplay]:9}}},n={};function i(e){var t=n[e];if(void 0!==t)return t.exports;var o=n[e]={exports:{}};return r[e](o,o.exports,i),o.exports}i.m=r,i.d=(e,t)=>{for(var r in t)i.o(t,r)&&!i.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},i.f={},i.e=e=>Promise.all(Object.keys(i.f).reduce(((t,r)=>(i.f[r](e,t),t)),[])),i.u=e=>(({78:"page_action-aggregate",147:"metrics-aggregate",242:"session-manager",317:"jserrors-aggregate",348:"page_view_timing-aggregate",412:"lazy-feature-loader",439:"async-api",538:"recorder",590:"session_replay-aggregate",675:"compressor",733:"session_trace-aggregate",786:"page_view_event-aggregate",873:"spa-aggregate",898:"ajax-aggregate"}[e]||e)+"."+{78:"ac76d497",147:"3dc53903",148:"1a20d5fe",242:"2a64278a",317:"49e41428",348:"bd6de33a",412:"2f55ce66",439:"30bd804e",538:"1b18459f",590:"cf0efb30",675:"ae9f91a8",733:"83105561",786:"06482edd",860:"03a8b7a5",873:"e6b09d52",898:"998ef92b"}[e]+"-1.236.0.min.js"),i.o=(e,t)=>Object.prototype.hasOwnProperty.call(e,t),e={},t="NRBA:",i.l=(r,n,o,a)=>{if(e[r])e[r].push(n);else{var s,c;if(void 0!==o)for(var u=document.getElementsByTagName("script"),d=0;d {s.onerror=s.onload=null,clearTimeout(h);var i=e[r];if(delete e[r],s.parentNode&&s.parentNode.removeChild(s),i&&i.forEach((e=>e(n))),t)return t(n)},h=setTimeout(l.bind(null,void 0,{type:"timeout",target:s}),12e4);s.onerror=l.bind(null,s.onerror),s.onload=l.bind(null,s.onload),c&&document.head.appendChild(s)}},i.r=e=>{"undefined"!=typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},i.j=364,i.p="https://js-agent.newrelic.com/",(()=>{var e={364:0,953:0};i.f.j=(t,r)=>{var n=i.o(e,t)?e[t]:void 0;if(0!==n)if(n)r.push(n[2]);else{var o=new Promise(((r,i)=>n=e[t]=[r,i]));r.push(n[2]=o);var a=i.p+i.u(t),s=new Error;i.l(a,(r=>{if(i.o(e,t)&&(0!==(n=e[t])&&(e[t]=void 0),n)){var o=r&&("load"===r.type?"missing":r.type),a=r&&r.target&&r.target.src;s.message="Loading chunk "+t+" failed.\n("+o+": "+a+")",s.name="ChunkLoadError",s.type=o,s.request=a,n[1](s)}}),"chunk-"+t,t)}};var t=(t,r)=>{var n,o,[a,s,c]=r,u=0;if(a.some((t=>0!==e[t]))){for(n in s)i.o(s,n)&&(i.m[n]=s[n]);if(c)c(i)}for(t&&t(r);u {i.r(o);var e=i(3325),t=i(5763);const r=Object.values(e.D);function n(e){const n={};return r.forEach((r=>{n[r]=function(e,r){return!1!==(0,t.Mt)(r,"".concat(e,".enabled"))}(r,e)})),n}var a=i(9144);var s=i(5546),c=i(385),u=i(8e3),d=i(5938),f=i(3960),l=i(50);class h extends d.W{constructor(e,t,r){let n=!(arguments.length>3&&void 0!==arguments[3])||arguments[3];super(e,t,r),this.auto=n,this.abortHandler,this.featAggregate,this.onAggregateImported,n&&(0,u.R)(e,r)}importAggregator(){let e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{};if(this.featAggregate||!this.auto)return;const r=c.il&&!0===(0,t.Mt)(this.agentIdentifier,"privacy.cookies_enabled");let n;this.onAggregateImported=new Promise((e=>{n=e}));const o=async()=>{let t;try{if(r){const{setupAgentSession:e}=await Promise.all([i.e(860),i.e(242)]).then(i.bind(i,3228));t=e(this.agentIdentifier)}}catch(e){(0,l.Z)("A problem occurred when starting up session manager. This page will not start or extend any session.",e)}try{if(!this.shouldImportAgg(this.featureName,t))return void(0,u.L)(this.agentIdentifier,this.featureName);const{lazyFeatureLoader:r}=await i.e(412).then(i.bind(i,8582)),{Aggregate:o}=await r(this.featureName,"aggregate");this.featAggregate=new o(this.agentIdentifier,this.aggregator,e),n(!0)}catch(e){(0,l.Z)("Downloading and initializing ".concat(this.featureName," failed..."),e),this.abortHandler?.(),n(!1)}};c.il?(0,f.b)((()=>o()),!0):o()}shouldImportAgg(r,n){return r!==e.D.sessionReplay||!1!==(0,t.Mt)(this.agentIdentifier,"session_trace.enabled")&&(!!n?.isNew||!!n?.state.sessionReplay)}}var g=i(7633),p=i(7894);class m extends h{static featureName=g.t9;constructor(r,n){let i=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];if(super(r,n,g.t9,i),("undefined"==typeof PerformanceNavigationTiming||c.Tt)&&"undefined"!=typeof PerformanceTiming){const n=(0,t.OP)(r);n[g.Dz]=Math.max(Date.now()-n.offset,0),(0,f.K)((()=>n[g.qw]=Math.max((0,p.z)()-n[g.Dz],0))),(0,f.b)((()=>{const t=(0,p.z)();n[g.OJ]=Math.max(t-n[g.Dz],0),(0,s.p)("timing",["load",t],void 0,e.D.pageViewTiming,this.ee)}))}this.importAggregator()}}var v=i(1117),b=i(1284);class y extends v.w{constructor(e){super(e),this.aggregatedData={}}store(e,t,r,n,i){var o=this.getBucket(e,t,r,i);return o.metrics=function(e,t){t||(t={count:0});return t.count+=1,(0,b.D)(e,(function(e,r){t[e]=w(r,t[e])})),t}(n,o.metrics),o}merge(e,t,r,n,i){var o=this.getBucket(e,t,n,i);if(o.metrics){var a=o.metrics;a.count+=r.count,(0,b.D)(r,(function(e,t){if("count"!==e){var n=a[e],i=r[e];i&&!i.c?a[e]=w(i.t,n):a[e]=function(e,t){if(!t)return e;t.c||(t=x(t.t));return t.min=Math.min(e.min,t.min),t.max=Math.max(e.max,t.max),t.t+=e.t,t.sos+=e.sos,t.c+=e.c,t}(i,a[e])}}))}else o.metrics=r}storeMetric(e,t,r,n){var i=this.getBucket(e,t,r);return i.stats=w(n,i.stats),i}getBucket(e,t,r,n){this.aggregatedData[e]||(this.aggregatedData[e]={});var i=this.aggregatedData[e][t];return i||(i=this.aggregatedData[e][t]={params:r||{}},n&&(i.custom=n)),i}get(e,t){return t?this.aggregatedData[e]&&this.aggregatedData[e][t]:this.aggregatedData[e]}take(e){for(var t={},r="",n=!1,i=0;i t.max&&(t.max=e),e 2&&void 0!==arguments[2])||arguments[2];super(e,r,j.t,n),c.il&&((0,t.OP)(e).initHidden=Boolean("hidden"===document.visibilityState),(0,N.N)((()=>(0,s.p)("docHidden",[(0,p.z)()],void 0,j.t,this.ee)),!0),(0,O.bP)("pagehide",(()=>(0,s.p)("winPagehide",[(0,p.z)()],void 0,j.t,this.ee))),this.importAggregator())}}var P=i(3081);class C extends h{static featureName=P.t9;constructor(e,t){let r=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];super(e,t,P.t9,r),this.importAggregator()}}var R,I=i(2210),k=i(1214),H=i(2177),L={};try{R=localStorage.getItem("__nr_flags").split(","),console&&"function"==typeof console.log&&(L.console=!0,-1!==R.indexOf("dev")&&(L.dev=!0),-1!==R.indexOf("nr_dev")&&(L.nrDev=!0))}catch(e){}function z(e){try{L.console&&z(e)}catch(e){}}L.nrDev&&H.ee.on("internal-error",(function(e){z(e.stack)})),L.dev&&H.ee.on("fn-err",(function(e,t,r){z(r.stack)})),L.dev&&(z("NR AGENT IN DEVELOPMENT MODE"),z("flags: "+(0,b.D)(L,(function(e,t){return e})).join(", ")));var M=i(6660);class B extends h{static featureName=M.t;constructor(r,n){let i=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];super(r,n,M.t,i),this.skipNext=0;try{this.removeOnAbort=new AbortController}catch(e){}const o=this;o.ee.on("fn-start",(function(e,t,r){o.abortHandler&&(o.skipNext+=1)})),o.ee.on("fn-err",(function(t,r,n){o.abortHandler&&!n[M.A]&&((0,I.X)(n,M.A,(function(){return!0})),this.thrown=!0,(0,s.p)("err",[n,(0,p.z)()],void 0,e.D.jserrors,o.ee))})),o.ee.on("fn-end",(function(){o.abortHandler&&!this.thrown&&o.skipNext>0&&(o.skipNext-=1)})),o.ee.on("internal-error",(function(t){(0,s.p)("ierr",[t,(0,p.z)(),!0],void 0,e.D.jserrors,o.ee)})),this.origOnerror=c._A.onerror,c._A.onerror=this.onerrorHandler.bind(this),c._A.addEventListener("unhandledrejection",(t=>{const r=function(e){let t="Unhandled Promise Rejection: ";if(e instanceof Error)try{return e.message=t+e.message,e}catch(t){return e}if(void 0===e)return new Error(t);try{return new Error(t+(0,D.P)(e))}catch(e){return new Error(t)}}(t.reason);(0,s.p)("err",[r,(0,p.z)(),!1,{unhandledPromiseRejection:1}],void 0,e.D.jserrors,this.ee)}),(0,O.m$)(!1,this.removeOnAbort?.signal)),(0,k.gy)(this.ee),(0,k.BV)(this.ee),(0,k.em)(this.ee),(0,t.OP)(r).xhrWrappable&&(0,k.Kf)(this.ee),this.abortHandler=this.#e,this.importAggregator()}#e(){this.removeOnAbort?.abort(),this.abortHandler=void 0}onerrorHandler(t,r,n,i,o){"function"==typeof this.origOnerror&&this.origOnerror(...arguments);try{this.skipNext?this.skipNext-=1:(0,s.p)("err",[o||new F(t,r,n),(0,p.z)()],void 0,e.D.jserrors,this.ee)}catch(t){try{(0,s.p)("ierr",[t,(0,p.z)(),!0],void 0,e.D.jserrors,this.ee)}catch(e){}}return!1}}function F(e,t,r){this.message=e||"Uncaught error with no additional information",this.sourceURL=t,this.line=r}let U=1;const q="nr@id";function G(e){const t=typeof e;return!e||"object"!==t&&"function"!==t?-1:e===c._A?0:(0,I.X)(e,q,(function(){return U++}))}function V(e){if("string"==typeof e&&e.length)return e.length;if("object"==typeof e){if("undefined"!=typeof ArrayBuffer&&e instanceof ArrayBuffer&&e.byteLength)return e.byteLength;if("undefined"!=typeof Blob&&e instanceof Blob&&e.size)return e.size;if(!("undefined"!=typeof FormData&&e instanceof FormData))try{return(0,D.P)(e).length}catch(e){return}}}var X=i(7243);class W{constructor(e){this.agentIdentifier=e,this.generateTracePayload=this.generateTracePayload.bind(this),this.shouldGenerateTrace=this.shouldGenerateTrace.bind(this)}generateTracePayload(e){if(!this.shouldGenerateTrace(e))return null;var r=(0,t.DL)(this.agentIdentifier);if(!r)return null;var n=(r.accountID||"").toString()||null,i=(r.agentID||"").toString()||null,o=(r.trustKey||"").toString()||null;if(!n||!i)return null;var a=(0,_.M)(),s=(0,_.Ht)(),c=Date.now(),u={spanId:a,traceId:s,timestamp:c};return(e.sameOrigin||this.isAllowedOrigin(e)&&this.useTraceContextHeadersForCors())&&(u.traceContextParentHeader=this.generateTraceContextParentHeader(a,s),u.traceContextStateHeader=this.generateTraceContextStateHeader(a,c,n,i,o)),(e.sameOrigin&&!this.excludeNewrelicHeader()||!e.sameOrigin&&this.isAllowedOrigin(e)&&this.useNewrelicHeaderForCors())&&(u.newrelicHeader=this.generateTraceHeader(a,s,c,n,i,o)),u}generateTraceContextParentHeader(e,t){return"00-"+t+"-"+e+"-01"}generateTraceContextStateHeader(e,t,r,n,i){return i+"@nr=0-1-"+r+"-"+n+"-"+e+"----"+t}generateTraceHeader(e,t,r,n,i,o){if(!("function"==typeof c._A?.btoa))return null;var a={v:[0,1],d:{ty:"Browser",ac:n,ap:i,id:e,tr:t,ti:r}};return o&&n!==o&&(a.d.tk=o),btoa((0,D.P)(a))}shouldGenerateTrace(e){return this.isDtEnabled()&&this.isAllowedOrigin(e)}isAllowedOrigin(e){var r=!1,n={};if((0,t.Mt)(this.agentIdentifier,"distributed_tracing")&&(n=(0,t.P_)(this.agentIdentifier).distributed_tracing),e.sameOrigin)r=!0;else if(n.allowed_origins instanceof Array)for(var i=0;i 2&&void 0!==arguments[2])||arguments[2];super(r,n,Z.t,i),(0,t.OP)(r).xhrWrappable&&(this.dt=new W(r),this.handler=(e,t,r,n)=>(0,s.p)(e,t,r,n,this.ee),(0,k.u5)(this.ee),(0,k.Kf)(this.ee),function(r,n,i,o){function a(e){var t=this;t.totalCbs=0,t.called=0,t.cbTime=0,t.end=E,t.ended=!1,t.xhrGuids={},t.lastSize=null,t.loadCaptureCalled=!1,t.params=this.params||{},t.metrics=this.metrics||{},e.addEventListener("load",(function(r){_(t,e)}),(0,O.m$)(!1)),c.IF||e.addEventListener("progress",(function(e){t.lastSize=e.loaded}),(0,O.m$)(!1))}function s(e){this.params={method:e[0]},T(this,e[1]),this.metrics={}}function u(e,n){var i=(0,t.DL)(r);i.xpid&&this.sameOrigin&&n.setRequestHeader("X-NewRelic-ID",i.xpid);var a=o.generateTracePayload(this.parsedOrigin);if(a){var s=!1;a.newrelicHeader&&(n.setRequestHeader("newrelic",a.newrelicHeader),s=!0),a.traceContextParentHeader&&(n.setRequestHeader("traceparent",a.traceContextParentHeader),a.traceContextStateHeader&&n.setRequestHeader("tracestate",a.traceContextStateHeader),s=!0),s&&(this.dt=a)}}function d(e,t){var r=this.metrics,i=e[0],o=this;if(r&&i){var a=V(i);a&&(r.txSize=a)}this.startTime=(0,p.z)(),this.listener=function(e){try{"abort"!==e.type||o.loadCaptureCalled||(o.params.aborted=!0),("load"!==e.type||o.called===o.totalCbs&&(o.onloadCalled||"function"!=typeof t.onload)&&"function"==typeof o.end)&&o.end(t)}catch(e){try{n.emit("internal-error",[e])}catch(e){}}};for(var s=0;s 1?e[1]=i:e.push(i)}else e[0]&&e[0].headers&&s(e[0].headers,n)&&(this.dt=n);function s(e,t){var r=!1;return t.newrelicHeader&&(e.set("newrelic",t.newrelicHeader),r=!0),t.traceContextParentHeader&&(e.set("traceparent",t.traceContextParentHeader),t.traceContextStateHeader&&e.set("tracestate",t.traceContextStateHeader),r=!0),r}}function x(e,t){this.params={},this.metrics={},this.startTime=(0,p.z)(),this.dt=t,e.length>=1&&(this.target=e[0]),e.length>=2&&(this.opts=e[1]);var r,n=this.opts||{},i=this.target;"string"==typeof i?r=i:"object"==typeof i&&i instanceof Y?r=i.url:c._A?.URL&&"object"==typeof i&&i instanceof URL&&(r=i.href),T(this,r);var o=(""+(i&&i instanceof Y&&i.method||n.method||"GET")).toUpperCase();this.params.method=o,this.txSize=V(n.body)||0}function A(t,r){var n;this.endTime=(0,p.z)(),this.params||(this.params={}),this.params.status=r?r.status:0,"string"==typeof this.rxSize&&this.rxSize.length>0&&(n=+this.rxSize);var o={txSize:this.txSize,rxSize:n,duration:(0,p.z)()-this.startTime};i("xhr",[this.params,o,this.startTime,this.endTime,"fetch"],this,e.D.ajax)}function E(t){var r=this.params,n=this.metrics;if(!this.ended){this.ended=!0;for(var o=0;o 2&&void 0!==arguments[2])||arguments[2];super(e,t,we.t,r),this.importAggregator()}}new class{constructor(e){let t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:(0,_.ky)(16);c._A?(this.agentIdentifier=t,this.sharedAggregator=new y({agentIdentifier:this.agentIdentifier}),this.features={},this.desiredFeatures=new Set(e.features||[]),this.desiredFeatures.add(m),Object.assign(this,(0,a.j)(this.agentIdentifier,e,e.loaderType||"agent")),this.start()):(0,l.Z)("Failed to initial the agent. Could not determine the runtime environment.")}get config(){return{info:(0,t.C5)(this.agentIdentifier),init:(0,t.P_)(this.agentIdentifier),loader_config:(0,t.DL)(this.agentIdentifier),runtime:(0,t.OP)(this.agentIdentifier)}}start(){const t="features";try{const r=n(this.agentIdentifier),i=[...this.desiredFeatures];i.sort(((t,r)=>e.p[t.featureName]-e.p[r.featureName])),i.forEach((t=>{if(r[t.featureName]||t.featureName===e.D.pageViewEvent){const n=function(t){switch(t){case e.D.ajax:return[e.D.jserrors];case e.D.sessionTrace:return[e.D.ajax,e.D.pageViewEvent];case e.D.sessionReplay:return[e.D.sessionTrace];case e.D.pageViewTiming:return[e.D.pageViewEvent];default:return[]}}(t.featureName);n.every((e=>r[e]))||(0,l.Z)("".concat(t.featureName," is enabled but one or more dependent features has been disabled (").concat((0,D.P)(n),"). This may cause unintended consequences or missing data...")),this.features[t.featureName]=new t(this.agentIdentifier,this.sharedAggregator)}})),(0,T.Qy)(this.agentIdentifier,this.features,t)}catch(e){(0,l.Z)("Failed to initialize all enabled instrument classes (agent aborted) -",e);for(const e in this.features)this.features[e].abortHandler?.();const r=(0,T.fP)();return delete r.initializedAgents[this.agentIdentifier]?.api,delete r.initializedAgents[this.agentIdentifier]?.[t],delete this.sharedAggregator,r.ee?.abort(),delete r.ee?.get(this.agentIdentifier),!1}}}({features:[J,m,S,class extends h{static featureName=oe;constructor(t,r){if(super(t,r,oe,!(arguments.length>2&&void 0!==arguments[2])||arguments[2]),!c.il)return;const n=this.ee;let i;(0,k.QU)(n),this.eventsEE=(0,k.em)(n),this.eventsEE.on(se,(function(e,t){this.bstStart=(0,p.z)()})),this.eventsEE.on(ae,(function(t,r){(0,s.p)("bst",[t[0],r,this.bstStart,(0,p.z)()],void 0,e.D.sessionTrace,n)})),n.on(ce+ne,(function(e){this.time=(0,p.z)(),this.startPath=location.pathname+location.hash})),n.on(ce+ie,(function(t){(0,s.p)("bstHist",[location.pathname+location.hash,this.startPath,this.time],void 0,e.D.sessionTrace,n)}));try{i=new PerformanceObserver((t=>{const r=t.getEntries();(0,s.p)(te,[r],void 0,e.D.sessionTrace,n)})),i.observe({type:re,buffered:!0})}catch(e){}this.importAggregator({resourceObserver:i})}},C,xe,B,class extends h{static featureName=de;constructor(e,r){if(super(e,r,de,!(arguments.length>2&&void 0!==arguments[2])||arguments[2]),!c.il)return;if(!(0,t.OP)(e).xhrWrappable)return;try{this.removeOnAbort=new AbortController}catch(e){}let n,i=0;const o=this.ee.get("tracer"),a=(0,k._L)(this.ee),s=(0,k.Lg)(this.ee),u=(0,k.BV)(this.ee),d=(0,k.Kf)(this.ee),f=this.ee.get("events"),l=(0,k.u5)(this.ee),h=(0,k.QU)(this.ee),g=(0,k.Gm)(this.ee);function m(e,t){h.emit("newURL",[""+window.location,t])}function v(){i++,n=window.location.hash,this[ve]=(0,p.z)()}function b(){i--,window.location.hash!==n&&m(0,!0);var e=(0,p.z)();this[pe]=~~this[pe]+e-this[ve],this[ye]=e}function y(e,t){e.on(t,(function(){this[t]=(0,p.z)()}))}this.ee.on(ve,v),s.on(be,v),a.on(be,v),this.ee.on(ye,b),s.on(ge,b),a.on(ge,b),this.ee.buffer([ve,ye,"xhr-resolved"],this.featureName),f.buffer([ve],this.featureName),u.buffer(["setTimeout"+le,"clearTimeout"+fe,ve],this.featureName),d.buffer([ve,"new-xhr","send-xhr"+fe],this.featureName),l.buffer([me+fe,me+"-done",me+he+fe,me+he+le],this.featureName),h.buffer(["newURL"],this.featureName),g.buffer([ve],this.featureName),s.buffer(["propagate",be,ge,"executor-err","resolve"+fe],this.featureName),o.buffer([ve,"no-"+ve],this.featureName),a.buffer(["new-jsonp","cb-start","jsonp-error","jsonp-end"],this.featureName),y(l,me+fe),y(l,me+"-done"),y(a,"new-jsonp"),y(a,"jsonp-end"),y(a,"cb-start"),h.on("pushState-end",m),h.on("replaceState-end",m),window.addEventListener("hashchange",m,(0,O.m$)(!0,this.removeOnAbort?.signal)),window.addEventListener("load",m,(0,O.m$)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",(function(){m(0,i>1)}),(0,O.m$)(!0,this.removeOnAbort?.signal)),this.abortHandler=this.#e,this.importAggregator()}#e(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}],loaderType:"spa"})})(),window.NRBA=o})(); window.jQuery || document.write(' ') CKEDITOR_BASEPATH='https://f1000research.com/js/vendor/ckeditor/' window.reactTheme = 'research'; window.MathJax = { CommonHTML: { linebreaks: { automatic: true } }, 'HTML-CSS': { linebreaks: { automatic: true } }, SVG: { linebreaks: { automatic: true } }, AuthorInit: function() { MathJax.Hub.Register.MessageHook('End Process', function () { let timeout = false; // holder for timeout id const delay = 250; // delay after event is "complete" to run callback const reflowMath = function() { const dispFormulas = document.querySelectorAll('.disp-formula.panel'); if (!dispFormulas) { return; } for (const dispFormula of dispFormulas) { const child = dispFormula.querySelector('.MathJax_Preview').nextSibling.firstChild; const isMultiline = MathJax.Hub.getAllJax(dispFormula)[0].root.isMultiline; if (dispFormula.offsetWidth < child.offsetWidth || isMultiline) { MathJax.Hub.Queue(['Rerender', MathJax.Hub, dispFormula]); } } }; window.addEventListener('resize', function() { clearTimeout(timeout); // clear the timeout timeout = setTimeout(reflowMath, delay); // start timing for event "completion" }); }); }, }; if (window.location.hash == '#_=_'){ window.location = window.location.href.split('#')[0] } !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function() {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)} ;if(!f._fbq)f._fbq=n; n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0; t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window, document,'script','https://connect.facebook.net/en_US/fbevents.js'); fbq('init', '1641728616063202'); fbq('track', "PixelInitialized", {}); (function(h,o,t,j,a,r){ h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)}; h._hjSettings={hjid:2318163,hjsv:6}; a=o.getElementsByTagName('head')[0]; r=o.createElement('script');r.async=1; r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv; a.appendChild(r); })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv='); search file_upload Submit your research search menu close search Browse Gateways & Collections How to Publish Submit your Research My Submissions Article Guidelines Article Guidelines (New Versions) Open Data, Software and Code Guidelines Open Data and Accessible Source Materials Guidelines (HSS) Open Data, Software and Code Guidelines (PSE) Prepublication Checks Production Process Posters and Slides Guidelines Document Guidelines Article Processing Charges Peer Review Finding Article Reviewers About How it Works For Reviewers Our Advisors Policies Glossary FAQs For Developers Newsroom Contact My Research Submissions Content and Tracking Alerts My Details Sign In file_upload Submit your research { "@context": "https://schema.org", "@type": "ScholarlyArticle", "mainEntityOfPage": { "@type": "WebPage", "@id": "https://f1000research.com/articles/14-1149" }, "headline": "Risk of second primary malignancies following radioactive iodine therapy in thyroid cancer: A meta-analysis of...", "datePublished": "2025-10-21T16:38:28", "dateModified": "2025-10-21T16:38:28", "author": [ { "@type": "Person", "name": "Aisyah Elliyanti" }, { "@type": "Person", "name": "Yulia Kurniawati" }, { "@type": "Person", "name": "Kevin Nathaniel Cuandra" }, { "@type": "Person", "name": "Dewa Ngakan Nyoman Karyana" }, { "@type": "Person", "name": "Melly Surya Oktaviani" }, { "@type": "Person", "name": "Christopher Daniel Tristan" } ], "publisher": { "@type": "Organization", "name": "F1000Research", "logo": { "@type": "ImageObject", "url": "https://f1000research.com/img/AMP/F1000Research_image.png", "height": 480, "width": 60 } }, "image": { "@type": "ImageObject", "url": "https://f1000research.com/img/AMP/F1000Research_image.png", "height": 1200, "width": 150 }, "description": "While the prognosis of thyroid cancer (TC) was generally excellent, there was a long-term concern regarding the risk of subsequent second primary malignancies (SPM) following radioactive iodine (RAI). This study aimed to comprehensively estimate the pooled risk of SPM occurrence following RAI therapy. The study searched the literature across three databases (PubMed, Scopus, and ScienceDirect), and was followed by citation searching. Original observational studies assessing the risk of SPM following RAI in TC were included. The Newcastle Ottawa scale was used for methodological assessment. STATA 17.0 was used for statistical analysis. A total of 18 studies encompassing 1,189,992 patients were included (638,275 in the RAI group and 551,717 in the non-RAI group). Pooled meta-analysis demonstrated no statistically significant increase in the risk of SPMs in the RAI-treated group, with a pooled RR of 1.07 (95% CI: 0.96 –1.21; p = 0.23). This result was deemed robust based on leave-one-out analysis. Subgroup analysis across publication year, follow-up duration (>10 years vs ≤10 years), population size, and SPM site (including breast, genitourinary, gastrointestinal-hepatobiliary, respiratory, skin, hematology, central nervous system, head and neck) consistently showed comparable results. There was no evidence of a significantly increased risk of SPM among TC survivors treated with RAI." } { "@context": "http://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": "1", "item": { "@id": "https://f1000research.com/", "name": "Home" } }, { "@type": "ListItem", "position": "2", "item": { "@id": "https://f1000research.com/browse/articles", "name": "Browse" } }, { "@type": "ListItem", "position": "3", "item": { "@id": "https://f1000research.com/articles/14-1149/v1", "name": "Risk of second primary malignancies following radioactive iodine therapy..." } } ] } Home Browse Risk of second primary malignancies following radioactive iodine therapy... ALL Metrics - Views Downloads Get PDF Get XML Cite How to cite this article Elliyanti A, Kurniawati Y, Cuandra KN et al. Risk of second primary malignancies following radioactive iodine therapy in thyroid cancer: A meta-analysis of 1,189,992 patients [version 1; peer review: awaiting peer review] . F1000Research 2025, 14 :1149 ( https://doi.org/10.12688/f1000research.172050.1 ) NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article. Close Copy Citation Details Export Export Citation Sciwheel EndNote Ref. Manager Bibtex ProCite Sente EXPORT Select a format first Track Share ▬ ✚ Systematic Review Risk of second primary malignancies following radioactive iodine therapy in thyroid cancer: A meta-analysis of 1,189,992 patients [version 1; peer review: awaiting peer review] Aisyah Elliyanti https://orcid.org/0000-0003-0812-8052 1 , Yulia Kurniawati 1 , Kevin Nathaniel Cuandra https://orcid.org/0009-0007-7785-7474 2 , Dewa Ngakan Nyoman Karyana https://orcid.org/0009-0007-9154-7413 3 , Melly Surya Oktaviani 2 , Christopher Daniel Tristan https://orcid.org/0009-0009-4105-8739 4 Aisyah Elliyanti https://orcid.org/0000-0003-0812-8052 1 , Yulia Kurniawati 1 , [...] Kevin Nathaniel Cuandra https://orcid.org/0009-0007-7785-7474 2 , Dewa Ngakan Nyoman Karyana https://orcid.org/0009-0007-9154-7413 3 , Melly Surya Oktaviani 2 , Christopher Daniel Tristan https://orcid.org/0009-0009-4105-8739 4 PUBLISHED 21 Oct 2025 Author details Author details 1 Nuclear Medicine Division of Radiology Department, Faculty of Medicine, Universitas Andalas, Padang, West Sumatra, Indonesia 2 Department of Medicine, Faculty of Medicine, Universitas Andalas, Padang, West Sumatra, Indonesia 3 Department of Medicine, Faculty of Medicine and Health Sciences, Universitas Mataram, Mataram, West Nusa Tenggara, Indonesia 4 Department of Medicine, Faculty of Medicine, Universitas Sebelas Maret, Surakarta, Central Java, Indonesia Aisyah Elliyanti Roles: Conceptualization, Project Administration, Supervision, Writing – Review & Editing Yulia Kurniawati Roles: Conceptualization, Supervision, Writing – Review & Editing Kevin Nathaniel Cuandra Roles: Data Curation, Formal Analysis, Methodology, Visualization, Writing – Original Draft Preparation Dewa Ngakan Nyoman Karyana Roles: Data Curation, Formal Analysis, Methodology, Visualization, Writing – Original Draft Preparation Melly Surya Oktaviani Roles: Investigation, Validation Christopher Daniel Tristan Roles: Data Curation, Formal Analysis, Investigation, Methodology, Validation, Visualization, Writing – Original Draft Preparation OPEN PEER REVIEW REVIEWER STATUS AWAITING PEER REVIEW This article is included in the Oncology gateway. Abstract While the prognosis of thyroid cancer (TC) was generally excellent, there was a long-term concern regarding the risk of subsequent second primary malignancies (SPM) following radioactive iodine (RAI). This study aimed to comprehensively estimate the pooled risk of SPM occurrence following RAI therapy. The study searched the literature across three databases (PubMed, Scopus, and ScienceDirect), and was followed by citation searching. Original observational studies assessing the risk of SPM following RAI in TC were included. The Newcastle Ottawa scale was used for methodological assessment. STATA 17.0 was used for statistical analysis. A total of 18 studies encompassing 1,189,992 patients were included (638,275 in the RAI group and 551,717 in the non-RAI group). Pooled meta-analysis demonstrated no statistically significant increase in the risk of SPMs in the RAI-treated group, with a pooled RR of 1.07 (95% CI: 0.96 –1.21; p = 0.23). This result was deemed robust based on leave-one-out analysis. Subgroup analysis across publication year, follow-up duration (>10 years vs ≤10 years), population size, and SPM site (including breast, genitourinary, gastrointestinal-hepatobiliary, respiratory, skin, hematology, central nervous system, head and neck) consistently showed comparable results. There was no evidence of a significantly increased risk of SPM among TC survivors treated with RAI. READ ALL READ LESS Keywords Meta-analysis, Radioactive iodine, Second primary malignancy, Thyroid cancer. Corresponding Author(s) Aisyah Elliyanti ( [email protected] ) Close Corresponding author: Aisyah Elliyanti Competing interests: No competing interests were disclosed. Grant information: This study was supported by the Institute for Research and Community Service (LPPM), Universitas Andalas, through the Research Program for the Fiscal Year 2025 (Grant No. 163/UN16.19/PT.01.01/2025). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Copyright: © 2025 Elliyanti A et al . This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. How to cite: Elliyanti A, Kurniawati Y, Cuandra KN et al. Risk of second primary malignancies following radioactive iodine therapy in thyroid cancer: A meta-analysis of 1,189,992 patients [version 1; peer review: awaiting peer review] . F1000Research 2025, 14 :1149 ( https://doi.org/10.12688/f1000research.172050.1 ) First published: 21 Oct 2025, 14 :1149 ( https://doi.org/10.12688/f1000research.172050.1 ) Latest published: 21 Oct 2025, 14 :1149 ( https://doi.org/10.12688/f1000research.172050.1 ) Introduction Thyroid cancer (TC) has been increasing globally over recent decades, mainly driven by greater detection of small papillary lesions due to improved imaging techniques and more extensive screening. 1 GLOBOCAN 2022 has established TC as the seventh most common malignancy worldwide, with an estimated 821,214 new cases and 47,507 deaths reported in that year. 2 While the prognosis of TC is generally excellent, with 10-year disease-specific survival rates often exceeding 90%, long-term survivors remain at risk of subsequent second primary malignancies (SPM). 3 , 4 SPM is defined as a new, histologically confirmed malignancy arising in a different anatomical site (non-synchronous) from the original thyroid carcinoma, and not a metastasis or recurrence. 5 Reported incidence of SPM in TC survivors varies widely, ranging from about 2.4% to over 19%, depending on patient demographics, length of follow-up, and whether or not radioactive iodine (RAI) therapy was used. 6 , 7 Given the long-expected survival after TC, even modest elevations in SPM risk may translate into meaningful excess morbidity and mortality over time. To date, only a limited number of meta-analyses have investigated the risk of SPM following RAI. For instance, Nappi et al. (2022) evaluated breast cancer as a second risk of cancer after RAI treatment and found no significant risk elevation. 8 However, that study was limited to a single tumor site and did not assess overall SPM risk. No comprehensive meta-analysis has yet synthesized evidence across all non-thyroidal SPMs (both solid and hematologic) while accounting for these potential sources of variation. Herein, the present study aims to comprehensively estimate the pooled risk of SPM occurrence following RAI therapy. Methods The study adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. 9 The protocol was registered in advance on PROSPERO (registration number CRD420251150102), and all methodological decisions reported here follow the outlined protocols. Search strategy and selection criteria PubMed, Scopus, and ScienceDirect databases were used as a comprehensive literature search database, from inception to March 2025, to identify studies that evaluate the risk of SPMs following RAI therapy in patients with TC. A search strategy was employed using a mix of keywords and MeSH (Medical Subject Headings) terms pertinent to thyroid cancer, radioactive iodine, and secondary primary malignancies. The specific search terms included: (“thyroid cancer” OR “thyroid carcinoma” OR “differentiated thyroid carcinoma”) AND (“radioactive iodine” OR “radioiodine” OR “I-131”) AND (“second primary malignancy” OR “second cancer” OR “second primary neoplasm”). Additionally, the reference lists of eligible articles and relevant reviews were manually screened to identify further studies. Eligibility criteria Studies were considered eligible in this study if they fulfilled inclusion criteria: (1) original observational articles; (2) enrolled patients with histologically confirmed TC; (3) compared patients who received RAI with those who did not; (4) reported the number of SPM events and total patients in each group or provided effect estimates (risk ratio [RR], hazard ratio [HR], or odds ratio [OR]) with 95% confidence intervals (CI); and (5) reported a minimum follow-up duration of at least 2 years after thyroid cancer diagnosis. Studies were excluded under the following criteria: (1) they reported only synchronous malignancies, recurrences, or metastases; (2) lacked a non-RAI comparison group; and (3) were case reports, editorials, reviews, or conference abstracts. Study selection, data extraction, and outcomes Two independent reviewers were responsible for screening the titles, abstracts, and full texts of the literature to determine eligibility and for extracting relevant data from the included studies. A third party resolved any discrepancies. The extracted data comprised the following elements: the first author, year of publication, country of study, study design, population size, number of patients who received RAI, number of patients who did not receive RAI, the number of SPM events in each group, and the mean or median duration of follow-up. The primary objective of the study was to evaluate the likelihood of patients diagnosed with TC developing non-thyroidal SPMs following treatment with RAI. This was compared to the risk faced by patients who did not receive RAI as part of their treatment regimen. The effect measure was the natural logarithm of the RR (logRR), which was pooled across studies and then back-transformed to RR for interpretability. Secondary outcomes included pooled RR estimates stratified by tumor site and the predefined subgroup variables. Risk of bias assessment The methodological quality of the studies included in the analysis was assessed using the Newcastle-Ottawa Scale (NOS), which evaluates three key domains: selection, comparability, and assessment of outcome/exposure. Studies that received a score of 7 points or higher were categorized as high-quality, while those scoring between 5 and 6 points were classified as moderate-quality. Studies with scores below 5 points were regarded as low quality. Two authors independently evaluated the risk of bias, and a third-party adjudicator resolved any discrepancies that emerged. Statistical analysis All statistical analyses were performed using Stata version 17.0 (StataCorp LLC, College Station, TX, USA). LogRRs and SEs were calculated for each study, and pooled using a random-effects model (DerSimonian–Laird method) to account for between-study heterogeneity. Results were presented as pooled RRs with 95% CIs. Statistical heterogeneity was evaluated using Cochran’s Q test (p < 0.10 indicating significant heterogeneity) and quantified with the I 2 statistic, with values of 25%, 50%, and 75% considered low, moderate, and high heterogeneity, respectively. Leave-one-out sensitivity analyses were conducted to evaluate the influence of individual studies on the overall pooled effect. Subgroup analyses were performed in Stata to explore differences in effect estimates across predefined study-level variables, including publication year, follow-up duration, and population size. A two-sided p-value of <0.05 was considered statistically significant. Results Search results and baseline characteristics A total of 2,361 records were identified from electronic databases. After removing duplicates and ineligible records, followed by screening and full-text assessment, 18 articles were included in this study. 10 – 27 Subsequent citation searching yielded two articles that were included in the current analysis. The complete screening process is outlined in the PRISMA flowchart ( Figure 1 ). Figure 1. The results of the article screening are based on the PRISMA protocol. A total of 1,189,992 patients diagnosed with thyroid cancer were included in this analysis, drawn from eighteen studies. Among these patients, 638,275 received treatment with RAI, whereas 551,717 did not undergo this treatment. The studies, published between 2003 and 2023, primarily utilized retrospective or population-based cohort designs and were conducted in various countries, including South Korea, the United States, several European nations, China, Taiwan, Israel, Saudi Arabia, and Brazil. Follow-up durations ranged from 2 to 16.2 years, with the majority of studies focusing on papillary or follicular thyroid carcinoma. Comprehensive baseline characteristics are presented in Table 1 . Table 1. Baseline characteristics of included studies. Author, year Study design Country RAI SPM RAI No RAI SPM No RAI Type of TC Follow-up Rubino et al., 2003 10 Retrospective cohort Swedish, Italian, and French 37,702 751 40,253 652 DTC (PTC or FTC) 13 (2–55) years Bhattacharyya and Chien, 2006 11 Cohort SEER 10,349 501 18,882 1,271 DTC (PTC and FTC) 61.84 months (mean) Cappagli et al., 2020 12 Retrospective cohort Italy 1050 78 46 3 DTC (PTC and FTC) 13.9 ± 9.5 years Hong et al., 2023 13 Retrospective cohort South Korea 147,747 8,322 215,481 11,063 TC 8.11 ± 3.48 years Kim et al., 2023 14 Retrospective cohort South Korea 100,448 6,148 117,329 5,772 TC 7.7 (5.5-10.3) years Lang et al., 2012 15 Cohort China 643 56 252 8 DTC (PTC or FTC) 93.5 months (range, 23.4–570.8) Lin et al., 2015 16 Cohort China 7,069 91 3,292 38 TC 6.58 years (IQR 4.40–9.12) Mei et al., 2021 17 Cohort SEER 51,212 2,289 52,814 2,339 DTC (PTC or FTC) 91 (57–133) months Molenaar et al., 2018 18 Cohort SEER 68,374 366 79,033 417 DTC (PTC or FTC) 6.6 (3.1-11.4) years Pasqual et al., 2022 (solid tumor) 19 Cohort SEER 14,877 764 12,173 760 DTC (PTC or FTC) 12.7 (IQR 4.8; 24.5) years Pasqual et al., 2022 (hematological malignancies) 19 Cohort SEER 14,477 65 17,694 81 DTC (PTC or FTC) 12.7 (IQR 4.8; 24.5) years Souza et al., 2015 20 Retrospective cohort Brazil 252 13 161 4 DTC (PTC or FTC) 11.0 ± 7.5 years Wu et al., 2023 21 Retrospective Cohort SEER 61,210 4,154 69,692 4,450 DTC (PTC or FTC) 85 (41-141) months Hakala et al., 2015 22 Retrospective cohort Finland 840 83 170 26 DTC (PTC or FTC) 16.2 ± 6.9 years Hirsch et al., 2016 23 Cohort Israel 1,335 132 296 29 DTC (PTC or FTC) 9.3 ± 9.6 years Ko et al., 2015 24 Cohort Taiwan 1,834 78 1,834 61 DTC (PTC or FTC) 5.55 ± 3.27 years Seo et al., 2021 25 Retrospective cohort South Korea 9,548 81 9,069 43 TC 79 months (IQR = 46–108 months) Silva-Viera et al., 2017 26 Retrospective cohort Portugal 1,570 108 461 22 DTC (PTC or FTC) 8.8 years (range 5.0–17.0 years) Al-Qahtani et al., 2015 27 Retrospective cohort Saudi 732 41 91 6 DTC (PTC or FTC) 8.05 years (range: 1.62-11.4) Table 2. Risk of bias assessment of the included studies using the Newcastle–Ottawa Scale (NOS). No Study (year) Selection (0–4) Comparability (0–2) Outcome (0–3) Total (0–9) Overall (Good/Fair/Poor) 1 Rubino et al., 2003 4 1 3 8 Good 2 Bhattacharyya and Chien, 2006 4 1 3 8 Good 3 Cappagli et al., 2020 3 1 2 6 Fair 4 Hong et al., 2023 4 1 3 8 Good 5 Kim et al., 2023 4 2 3 9 Good 6 Lang et al., 2012 3 1 2 6 Fair 7 Lin et al., 2016 4 1 3 8 Good 8 Mei et al., 2021 3 1 2 6 Fair 9 Molenaar et al., 2018 4 2 3 9 Good 10 Pasqual et al., 2022 4 2 3 9 Good 11 Souza et al., 2016 3 1 2 6 Fair 12 Wu et al., 2023 4 1 3 8 Good 13 Hakala et al., 2015 4 1 3 8 Good 14 Hirsch et al., 2016 3 1 2 6 Fair 15 Ko et al., 2015 4 1 3 8 Good 16 Seo et al., 2021 4 1 3 8 Good 17 Silva-Vieira et al., 2017 3 1 2 6 Fair 18 Al-Qahtani et al., 2015 2 0 1 3 Poor Quality assessment of included studies The evaluation of the study quality revealed that 11 studies were rated as of good quality, with scores ranging from 7 to 9; six were considered of fair quality, receiving scores of 5 to 6; and one was identified as of poor quality, earning a score of 3 ( Table 2 ). Most population-based studies (e.g., Rubino et al. 2003; Bhattacharyya & Chien, 2006; Kim et al., 2023; Pasqual et al., 2022) demonstrated clear cohort selection, strong outcome ascertainment through cancer registries, and adequate follow-up durations. In contrast, several institutional studies faced challenges due to limited sample sizes and insufficient adjustment for confounding variables. Risk of SPM following RAI The pooled analysis revealed no statistically significant elevation in the risk of SPMs among the RAI-treated cohort. The pooled RR was calculated to be 1.07 (95% confidence interval: 0.96–1.21; p = 0.23), with substantial heterogeneity noted (I 2 = 95.96%; see Figure 2 ). Leave-one-out sensitivity analysis yielded a robust result, as the sequential omission of each study resulted in a pooled logRR that remained consistent with all comparable p-values ( Figure 3 ). Figure 2. Forest plot of the association between RAI therapy and the risk of SPMs in TC survivors. Figure 3. Leave-one-out sensitivity analysis of the association between RAI therapy and the risk of SPMs in TC survivors. Subgroup analyses were performed to investigate potential factors contributing to the heterogeneity in the relationship between RAI therapy and the incidence of SPMs among TC survivors, as detailed in Table 3 . No significant differences were observed by publication year (≤2015: logRR = 0.08; >2015: 0.07), follow-up duration (≤10 years: 0.08; >10 years: –0.03), or population size (≤10,000: 0.17; >10,000: 0.04). Similarly, site-specific analyses showed no significant increase in risk for any tumor group, including breast (–0.09), genitourinary (0.36), gastrointestinal/hepatobiliary (–0.15), respiratory (–0.22), skin (–0.02), hematologic (–0.16), central nervous system (0.03), and head and neck (0.15). Overall, none of the predefined subgroups significantly modified the association between RAI therapy and SPM risk. Table 3. Subgroup analysis of the association between RAI therapy and the risk of SPMs in TC survivors. Variable No. studies LogRR (95%CI) I 2 (%) Z p-value Publication year ≤2015 8 0.08 (-0.21, 0.38) 90.08% 0.56 0.58 >2015 11 0.07 (-0.01, 0.15) 90.32% 1.63 0.10 Follow-up duration ≤10 years 13 0.08 (-0.01, 0.17) 91.71% 1.73 0.08 >10 years 6 -0.03 (-0.30, 0.23) 86.23% -0.24 0.81 Population ≤10,000 8 0.17 (-0.13, 0.47) 57.76% 1.11 0.27 >10,000 11 0.04 (-0.05, 0.13) 94.28% 0.86 0.39 SPM site Breast 6 -0.09 (-0.37, 0.18) 55.21% -0.67 0.51 Genitourinary 6 0.36 (-0.27, 0.99) 86.70% 1.13 0.26 Gastrointestinal and hepatobiliary 6 -0.15 (-0.64, 0.33) 74.36% -0.63 0.53 Respiratory 4 -0.22 (-0.65, 0.21) 29.81% -1.01 0.31 Skin 4 -0.02 (-0.68, 0.64) 55.63% -0.05 0.96 Hematology 8 -0.16 (-0.46-0.15) 68.73% 1.01 0.31 CNS 3 0.03 (-0.70, 0.76) 25.53% 0.07 0.94 Head and neck 5 0.15 (-0.50, 0.80) 19.52% 0.45 0.65 Publication bias The evaluation of publication bias was conducted by creating a funnel plot and performing Egger’s regression test. The funnel plot indicated an approximately symmetrical distribution of effect sizes around the pooled estimate, with only minor deviations among studies that had larger standard errors, suggesting the absence of significant asymmetry (see Figure 4 ). Furthermore, Egger’s regression test did not indicate any evidence of small-study effects, with a bias coefficient of -0.53 (95% CI: -2.66 to 1.60; p = 0.609). Figure 4. Funnel plot assessing publication bias in the meta-analysis of RAI therapy and the risk of SPMs in TC survivors. Discussion This systematic review and meta-analysis, encompassing 18 cohort studies and over 1.1 million TC survivors, found no statistically significant increase in the risk of SPM associated with RAI therapy. Our subgroup analyses, by publication year, follow-up duration, population size, and SPM tumor site, revealed a consistent effect across all potential confounders, highlighting the safety profile of RAI. These findings align with prior large population-based studies, such as those by Rubino et al. (2003) and de Vathaire et al. (1997), which reported no significant overall increase in SPM risk after RAI despite modest elevations for certain organ-specific cancers. 10 , 28 Conversely, some studies have suggested a dose-related increase in SPM risk, particularly for leukemia or salivary gland cancers, at high cumulative activities (>150 mCi). However, most of these studies involved relatively small cohorts and reported few SPM events, raising concerns about statistical power and the robustness of those associations. 10 , 29 , 30 Our findings therefore provide more substantial evidence, derived from aggregated data, that the association between RAI and subsequent malignancies is likely weak or absent at the population level. Several limitations of the included evidence warrant consideration. First, the predominance of retrospective and registry-based designs introduces potential for residual confounding, especially regarding cumulative RAI dose, radiation from surveillance imaging, and lifestyle factors such as smoking or obesity. Second, many studies lacked detailed dose stratification, which prevented the assessment of dose–response relationships. Third, follow-up durations varied widely (2–16 years), and some cohorts may not have had sufficient latency to capture late-onset SPMs. Finally, heterogeneity in outcome ascertainment (e.g., variable cancer registry linkages) could have contributed to the high I 2 observed. From a clinical perspective, our findings suggest that RAI therapy should not be withheld from appropriate DTC patients out of concern for inducing second malignancies, particularly at commonly used doses. The ongoing heterogeneity in the findings highlights the importance of exercising caution when generalizing these results. Future investigations should prioritize large-scale pooled analyses that employ standardized definitions of SPM, incorporate long-term follow-up periods surpassing 20 years, and utilize detailed dose data. This approach is essential to elucidate potential dose-response thresholds related to risk. Additionally, molecular epidemiological studies may help identify susceptible subgroups (e.g., younger patients, genetic predispositions) who may be at an increased risk of radiation-induced malignancies. Conclusion Our meta-analysis showed substantial evidence indicating there was no significant elevation in the risk of SPM among TC survivors who underwent RAI therapy. These results endorse the ongoing application of RAI in suitably selected TC patients. However, it also emphasizes the need for tailored risk-benefit evaluations and ongoing surveillance, particularly for individuals classified within higher-risk subgroups. Underlying data Zenodo: Risk of second primary malignancies following radioactive iodine therapy in thyroid cancer: A meta-analysis of 1,189,992 patients. Doi: https://doi.org/10.5281/zenodo.17350685 31 This project contains the following underlying data: • PRISMA_2020_checklist.pdf • Breast.xlsx • CNS.xlsx • Follow-up less 10.xlsx • Follow-up more 10.xlsx • Gastrointestinal and Hepatobilier.xlsx • Genitourinary.xlsx • Head and neck.xlsx • Hemato.xlsx • Large population.xlsx • Publication less 2015.xlsx • Publication more 2015.xlsx • Respiratory.xlsx • Skin.xlsx • Small population.xlsx Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0). Reporting guidelines Zenodo: Risk of second primary malignancies following radioactive iodine therapy in thyroid cancer: A meta-analysis of 1,189,992 patients, Doi: https://doi.org/10.5281/zenodo.17361573 32 The Project contains the following reporting guidelines: • PRISMA Flow.jpg Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0). Zenodo: Risk of second primary malignancies following radioactive iodine therapy in thyroid cancer: A meta-analysis of 1,189,992 patients, Doi: https://doi.org/10.5281/zenodo.17361311 33 The Project contains the following reporting guidelines: • PRISMA Checklist Updated.docx Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0). Acknowledgements The authors would like to express their sincere gratitude to the Institute for Research and Community Service (LPPM), Universitas Andalas, for supporting this work through the Research Program for Fiscal Year 2025 (Grant No. 423/UN16.19/PT.01.03/PAR/2025). References 1. Kristollari K, Paul AA, Angel S, et al. : Conventional and Emerging Diagnostic Approaches for Differentiated Thyroid Carcinoma. Chemosensors. 2024; 12 (11): 229. Publisher Full Text 2. International Agency for Research on Cancer: Global Cancer Observatory Worldwide: Cancer Today. Lyon, France: IARC; 2022. Reference Source 3. Cabanillas ME, McFadden DG, Durante C: Thyroid cancer. Lancet. 2016; 388 (10061): 2783–2795. Publisher Full Text 4. Cooper DS, Doherty GM, Haugen BR, et al. : Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. In: American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2009; 19 (11): 1167–1214. PubMed Abstract | Publisher Full Text 5. Reinecke MJ, Ahlers G, Burchert A, et al. : Second Primary Malignancies Induced by Radioactive Iodine Treatment of Differentiated Thyroid Carcinoma—A Critical Review and Evaluation of the Existing Evidence. Eur. J. Nucl. Med. Mol. Imaging. 2022; 49 : 3247–3256. PubMed Abstract | Publisher Full Text | Free Full Text 6. Okeke F, Nriagu VC, Nwaneki CM, et al. : Factors that determine multiple primary cancers in the adult population in the United States. Cureus. 2023; 15 (9): e44993. PubMed Abstract | Publisher Full Text 7. Murphy CC, Gerber DE, Pruitt SL: Prevalence of prior cancer among persons newly diagnosed with cancer: an initial report from the surveillance, epidemiology, and end results program. JAMA Oncol. 2018; 4 (6): 832–836. PubMed Abstract | Publisher Full Text | Free Full Text 8. Nappi C, Klain M, Cantoni V, et al. : Risk of primary breast cancer in patients with differentiated thyroid cancer undergoing radioactive iodine therapy: a systematic review and meta-analysis. Eur. J. Nucl. Med. Mol. Imaging. 2022 Apr; 49 (5): 1630–1639. PubMed Abstract | Publisher Full Text 9. Page MJ, McKenzie JE, Bossuyt PM, et al. : The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372 : n71. PubMed Abstract | Publisher Full Text | Free Full Text 10. Rubino C, de Vathaire F , Dottorini ME, et al. : Second primary malignancies in thyroid cancer patients. Br. J. Cancer. 2003 Nov 3; 89 (9): 1638–1644. PubMed Abstract | Publisher Full Text | Free Full Text 11. Bhattacharyya N, Chien W: Risk of second primary malignancy after radioactive iodine treatment for differentiated thyroid carcinoma. Ann. Otol. Rhinol. Laryngol. 2006 Aug; 115 (8): 607–610. PubMed Abstract | Publisher Full Text 12. Cappagli V, Caldarella A, Manneschi G, et al. : Nonthyroidal second primary malignancies in differentiated thyroid cancer patients: Is the incidence increased comparing to the general population and could it be a radioiodine therapy consequence? Int. J. Cancer. 2020 Nov 15; 147 (10): 2838–2846. PubMed Abstract | Publisher Full Text 13. Hong CM, Son J, Hyun MK, et al. : Second Primary Malignancy After Radioiodine Therapy in Thyroid Cancer Patient: A Nationwide Study. Nucl. Med. Mol. Imaging. 2023 Dec; 57 (6): 275–286. PubMed Abstract | Publisher Full Text | Free Full Text 14. Kim KJ, Kim KJ, Choi J, et al. : Linear association between radioactive iodine dose and second primary malignancy risk in thyroid cancer. J. Natl. Cancer Inst. 2023 Jun 8; 115 (6): 695–702. PubMed Abstract | Publisher Full Text | Free Full Text 15. Lang BH, Wong IO, Wong KP, et al. : Risk of second primary malignancy in differentiated thyroid carcinoma treated with radioactive iodine therapy. Surgery. 2012 Jun; 151 (6): 844–850. Publisher Full Text 16. Lin CY, Lin CL, Huang WS, et al. : Risk of Breast Cancer in Patients with Thyroid Cancer Receiving or Not Receiving 131I Treatment: A Nationwide Population-Based Cohort Study. J. Nucl. Med. 2016 May; 57 (5): 685–690. Publisher Full Text 17. Mei X, Yao X, Feng F, et al. : Risk and outcome of subsequent malignancies after radioactive iodine treatment in differentiated thyroid cancer patients. BMC Cancer. 2021 May 13; 21 (1): 543. PubMed Abstract | Publisher Full Text | Free Full Text 18. Molenaar RJ, Sidana S, Radivoyevitch T, et al. : Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer. J. Clin. Oncol. 2018 Jun 20; 36 (18): 1831–1839. PubMed Abstract | Publisher Full Text | Free Full Text 19. Pasqual E, Schonfeld S, Morton LM, et al. : Association Between Radioactive Iodine Treatment for Pediatric and Young Adulthood Differentiated Thyroid Cancer and Risk of Second Primary Malignancies. J. Clin. Oncol. 2022 May 1; 40 (13): 1439–1449. PubMed Abstract | Publisher Full Text | Free Full Text 20. Souza MC, Momesso DP, Vaisman F, et al. : Is radioactive iodine- 131 treatment related to the occurrence of non-synchronous second primary malignancy in patients with differentiated thyroid cancer? Arch. Endocrinol. Metab. 2016 Feb; 60 (1): 9–15. PubMed Abstract | Publisher Full Text | Free Full Text 21. Wu W, Li S, Xu K, et al. : Hazard ratios of second primary malignancy after radioiodine for differentiated thyroid carcinoma: a large-cohort retrospective study. Endokrynol. Pol. 2023; 74 (3): 260–270. PubMed Abstract | Publisher Full Text 22. Hakala TT, Sand JA, Jukkola A, et al. : Increased risk of certain second primary malignancies in patients treated for well-differentiated thyroid cancer. Int. J. Clin. Oncol. 2016 Apr; 21 (2): 231–239. PubMed Abstract | Publisher Full Text 23. Hirsch D, Shohat T, Gorshtein A, et al. : Incidence of Nonthyroidal Primary Malignancy and the Association with (131) I Treatment in Patients with Differentiated Thyroid Cancer. Thyroid. 2016 Aug; 26 (8): 1110–1116. PubMed Abstract | Publisher Full Text 24. Ko KY, Kao CH, Lin CL, et al. : (131) I treatment for thyroid cancer and the risk of developing salivary and lacrimal gland dysfunction and a second primary malignancy: a nationwide population-based cohort study. Eur. J. Nucl. Med. Mol. Imaging. 2015 Jul; 42 (8): 1172–1178. PubMed Abstract | Publisher Full Text 25. Seo GH, Kong KA, Kim BS, et al. : Radioactive Iodine Treatment for Children and Young Adults with Thyroid Cancer in South Korea: A Population-based Study. J. Clin. Endocrinol. Metab. 2021 Jun 16; 106 (7): e2580–e2588. PubMed Abstract | Publisher Full Text 26. Silva-Vieira M, Carrilho Vaz S, Esteves S, et al. : Second Primary Cancer in Patients with Differentiated Thyroid Cancer: Does Radioiodine Play a Role? Thyroid. 2017 Aug; 27 (8): 1068–1076. PubMed Abstract | Publisher Full Text 27. Al-Qahtani KH, Al-Asiri M, Tunio MA, et al. : Prevalence and treatment outcomes of second primary malignancies in Saudi patients with differentiated thyroid cancers. Saudi Med. J. 2015 Apr; 36 (4): 442–448. PubMed Abstract | Publisher Full Text | Free Full Text 28. de Vathaire F , Schlumberger M, Delisle MJ, et al. : Leukaemias and cancers following iodine-131 administration for thyroid cancer. Br. J. Cancer. 1997; 75 (5): 734–739. PubMed Abstract | Publisher Full Text | Free Full Text 29. Iyer NG, Morris LG, Tuttle RM, et al. : Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer. 2011 Oct 1; 117 (19): 4439–4446. PubMed Abstract | Publisher Full Text | Free Full Text 30. Brown AP, Chen J, Hitchcock YJ, et al. : The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 2008 Feb; 93 (2): 504–515. PubMed Abstract | Publisher Full Text 31. Elliyanti A, et al. : Risk of second primary malignancies following radioactive iodine therapy in thyroid cancer: A meta-analysis of 1,189,992 patients. [Data set]. Zenodo. 2025. Publisher Full Text 32. Elliyanti A, et al. : [PRISMA Flow] Risk of second primary malignancies following radioactive iodine therapy in thyroid cancer: A meta-analysis of 1,189,992 patients. Zenodo. 2025. Publisher Full Text 33. Elliyanti A, et al. : [PRISMA checklist] Risk of second primary malignancies following radioactive iodine therapy in thyroid cancer: A meta-analysis of 1,189,992 patients. Zenodo. 2025. Publisher Full Text Comments on this article Comments (0) Version 1 VERSION 1 PUBLISHED 21 Oct 2025 ADD YOUR COMMENT Comment Author details Author details 1 Nuclear Medicine Division of Radiology Department, Faculty of Medicine, Universitas Andalas, Padang, West Sumatra, Indonesia 2 Department of Medicine, Faculty of Medicine, Universitas Andalas, Padang, West Sumatra, Indonesia 3 Department of Medicine, Faculty of Medicine and Health Sciences, Universitas Mataram, Mataram, West Nusa Tenggara, Indonesia 4 Department of Medicine, Faculty of Medicine, Universitas Sebelas Maret, Surakarta, Central Java, Indonesia Aisyah Elliyanti Roles: Conceptualization, Project Administration, Supervision, Writing – Review & Editing Yulia Kurniawati Roles: Conceptualization, Supervision, Writing – Review & Editing Kevin Nathaniel Cuandra Roles: Data Curation, Formal Analysis, Methodology, Visualization, Writing – Original Draft Preparation Dewa Ngakan Nyoman Karyana Roles: Data Curation, Formal Analysis, Methodology, Visualization, Writing – Original Draft Preparation Melly Surya Oktaviani Roles: Investigation, Validation Christopher Daniel Tristan Roles: Data Curation, Formal Analysis, Investigation, Methodology, Validation, Visualization, Writing – Original Draft Preparation Competing interests No competing interests were disclosed. Grant information This study was supported by the Institute for Research and Community Service (LPPM), Universitas Andalas, through the Research Program for the Fiscal Year 2025 (Grant No. 163/UN16.19/PT.01.01/2025). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Article Versions (1) version 1 Published: 21 Oct 2025, 14:1149 https://doi.org/10.12688/f1000research.172050.1 Copyright © 2025 Elliyanti A et al . This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Download Export To Sciwheel Bibtex EndNote ProCite Ref. Manager (RIS) Sente metrics Views Downloads F1000Research - - PubMed Central info_outline Data from PMC are received and updated monthly. - - Citations open_in_new 0 open_in_new 0 open_in_new SEE MORE DETAILS CITE how to cite this article Elliyanti A, Kurniawati Y, Cuandra KN et al. Risk of second primary malignancies following radioactive iodine therapy in thyroid cancer: A meta-analysis of 1,189,992 patients [version 1; peer review: awaiting peer review] . F1000Research 2025, 14 :1149 ( https://doi.org/10.12688/f1000research.172050.1 ) NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS track receive updates on this article Track an article to receive email alerts on any updates to this article. TRACK THIS ARTICLE Share Open Peer Review Current Reviewer Status: AWAITING PEER REVIEW AWAITING PEER REVIEW ? Key to Reviewer Statuses VIEW HIDE Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Comments on this article Comments (0) Version 1 VERSION 1 PUBLISHED 21 Oct 2025 ADD YOUR COMMENT Comment keyboard_arrow_left keyboard_arrow_right Open Peer Review Reviewer Status AWAITING PEER REVIEW Comments on this article All Comments (0) Add a comment Sign up for content alerts Sign Up You are now signed up to receive this alert Browse by related subjects Alongside their report, reviewers assign a status to the article: Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions Adjust parameters to alter display View on desktop for interactive features Includes Interactive Elements View on desktop for interactive features Competing Interests Policy Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: Examples of 'Non-Financial Competing Interests' Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper. You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors. You are a close professional associate of any of the authors (e.g. scientific mentor, recent student). You work at the same institute as any of the authors. You hope/expect to benefit (e.g. favour or employment) as a result of your submission. You are an Editor for the journal in which the article is published. Examples of 'Financial Competing Interests' You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements. You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors. You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on. Stay Updated Sign up for content alerts and receive a weekly or monthly email with all newly published articles Register with F1000Research Already registered? Sign in Not now, thanks close PLEASE NOTE If you are an AUTHOR of this article, please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a “User Comment”. If you are a REVIEWER of this article, please check that you have signed in with the account associated with this article and then go to your account to submit your report, please do not post your review here. If you do not have access to your original account, please contact us . All commenters must hold a formal affiliation as per our Policies . The information that you give us will be displayed next to your comment. User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the User Comment Terms and Conditions . Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available. I accept the User Comment Terms and Conditions Please confirm that you accept the User Comment Terms and Conditions. Affiliation ✕ refresh Please enter your institution. Note: To add your institution or organisation, start typing the name and then select the correct name from the list. Where applicable, the name will appear in both the original language and in English. Do not paste in the name. If the name does not appear in the drop-down list, we will display the information you have entered. ✕ refresh Country/Region * USA UK Canada China France Germany Afghanistan Aland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory British Virgin Islands Brunei Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Cook Islands Costa Rica Cote d'Ivoire Croatia Cuba Cyprus Czech Republic Democratic Republic of the Congo Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Federated States of Micronesia Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and Mcdonald Islands Holy See (Vatican City State) Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kosovo (Serbia and Montenegro) Kuwait Kyrgyzstan Lao People's Democratic Republic Latvia Lebanon Lesotho Liberia Libya Liechtenstein Lithuania Luxembourg Macao Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Minor Outlying Islands of the United States Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island North Korea North Macedonia Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Reunion Romania Russian Federation Rwanda Saint Helena Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Is South Korea South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand The Gambia The Netherlands Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu UK USA Uganda Ukraine United Arab Emirates United States Virgin Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam Wallis and Futuna West Bank and Gaza Strip Western Sahara Yemen Zambia Zimbabwe Please select your country/region. You must enter a comment. Competing Interests Please disclose any competing interests that might be construed to influence your judgment of the article's or peer review report's validity or importance. Competing Interests Policy Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: Examples of 'Non-Financial Competing Interests' Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper. You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors. You are a close professional associate of any of the authors (e.g. scientific mentor, recent student). You work at the same institute as any of the authors. You hope/expect to benefit (e.g. favour or employment) as a result of your submission. You are an Editor for the journal in which the article is published. Examples of 'Financial Competing Interests' You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements. You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors. You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on. Please state your competing interests The comment has been saved. An error has occurred. Please try again. Cancel Post var lTitle = "Risk of second primary malignancies following...".replace("'", ''); var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/14-1149/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by '); var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/14-1149/v1&title=" + encodeURIComponent(lTitle); var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/14-1149/v1" + "&title=" + encodeURIComponent(lTitle); linkedInUrl += encodeURIComponent('Elliyanti A et al.'); var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; var addthis_config = { ui_offset_top: offsetTop, services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com", services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com", services_custom : [ { name: "LinkedIn", url: linkedInUrl, icon:"/img/icon/at_linkedin.svg" }, { name: "Mendeley", url: "http://www.mendeley.com/import/?url=https://f1000research.com/articles/14-1149/v1/mendeley", icon:"/img/icon/at_mendeley.svg" }, { name: "Reddit", url: redditUrl, icon:"/img/icon/at_reddit.svg" }, ] }; var addthis_share = { url: "https://f1000research.com/articles/14-1149", templates : { twitter : "Risk of second primary malignancies following radioactive iodine.... Elliyanti A et al., published by " + "@F1000Research" + ", https://f1000research.com/articles/14-1149/v1" } }; if (typeof(addthis) != "undefined"){ addthis.addEventListener('addthis.ready', checkCount); addthis.addEventListener('addthis.menu.share', checkCount); } $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter); $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url); $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url); $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url); $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url); function checkCount(){ setTimeout(function(){ $(".addthis_button_expanded").each(function(){ var count = $(this).text(); if (count !== "" && count != "0") $(this).removeClass("is-hidden"); else $(this).addClass("is-hidden"); }); }, 1000); } close How to cite this report {{reportCitation}} Cancel Copy Citation Details $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');}); $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');}); $.get("/articles/acj/172050/189735") new F1000.Clipboard(); new F1000.ThesaurusTermsDisplay("articles", "article", "189735"); $(document).ready(function() { $( "#frame1" ).on('load', function() { var mydiv = $(this).contents().find("div"); var h = mydiv.height(); console.log(h) }); var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"), titleLivingFigure = tooltipLivingFigure.attr("title"); tooltipLivingFigure.simpletip({ fixed: true, position: ["-115", "30"], baseClass: 'small-tooltip', content:titleLivingFigure + " " }); tooltipLivingFigure.removeAttr("title"); $("body").on("click", ".cite-living-figure", function(e) { e.preventDefault(); var ref = $(this).attr("data-ref"); $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200); }); $("body").on("click", ".close-cite-living-figure", function(e) { e.preventDefault(); $(this).closest(".popup-window-wrapper").fadeOut(200); }); $(document).on("mouseup", function(e) { var metricsContainer = $(".article-metrics-popover-wrapper"); if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) { $(".article-metrics-close-button").click(); } }); var articleId = $('#articleId').val(); if($("#main-article-count-box").attachArticleMetrics) { $("#main-article-count-box").attachArticleMetrics(articleId, { articleMetricsView: true }); } }); var figshareWidget = $(".new_figshare_widget"); if (figshareWidget.length > 0) { window.figshare.load("f1000", function(Widget) { // Select a tag/tags defined in your page. In this tag we will place the widget. _.map(figshareWidget, function(el){ var widget = new Widget({ articleId: $(el).attr("figshare_articleId") //height:300 // this is the height of the viewer part. [Default: 550] }); widget.initialize(); // initialize the widget widget.mount(el); // mount it in a tag that's on your page // this will save the widget on the global scope for later use from // your JS scripts. This line is optional. //window.widget = widget; }); }); } close Error Close Add Reset F1000.MICROSERVICES.AFFILIATION = ''; $(document).ready(function () { $('.js-affiliations-form').each((index, form) => { new AffiliationForm({ formId: form.id, institutionErrorSelector: '.comment-enter-institution', departmentErrorSelector: '.comment-enter-department', placeSelector: '.js-add-comment-place', stateSelector: '.js-add-comment-state', zipCodeSelector: '.js-add-comment-zipcode', countrySelector: '.js-add-comment-country', countryErrorSelector: '.comment-enter-country', }); }); }); $(document).ready(function () { var reportIds = { "467887": 0, "431534": 0, "467886": 0, "431535": 0, "467885": 0, "472236": 0, "431533": 0, "472235": 0, "472234": 0, "472233": 0, "431542": 0, "431540": 0, "431541": 0, "431538": 0, "431539": 0, "431536": 0, "431537": 0, "437822": 0, "426430": 0, "437823": 0, "426431": 0, "437820": 0, "426428": 0, "437821": 0, "426429": 0, "437818": 0, "437819": 0, "433606": 0, "433607": 0, "429383": 0, "433604": 0, "426436": 0, "426437": 0, "433605": 0, "437826": 0, "426434": 0, "437827": 0, "426435": 0, "437824": 0, "426432": 0, "437825": 0, "426433": 0, "429390": 0, "429391": 0, "433612": 0, "429388": 0, "433613": 0, "429389": 0, "433610": 0, "429386": 0, "433611": 0, "429387": 0, "433608": 0, "429384": 0, "433609": 0, "429385": 0, "429392": 0, "435806": 0, "435807": 0, "435804": 0, "435805": 0, "435802": 0, "435803": 0, "435801": 0, "435810": 0, "435808": 0, "435809": 0, }; $(".referee-response-container,.js-referee-report").each(function(index, el) { var reportId = $(el).attr("data-reportid"), reportCount = reportIds[reportId] || 0; $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount); }); var uuidInput = $("#article_uuid"), oldUUId = uuidInput.val(), newUUId = "2e520f19-737b-4516-8fa0-9c716c4501e5"; uuidInput.val(newUUId); $("a[href*='article_uuid=']").each(function(index, el) { var newHref = $(el).attr("href").replace(oldUUId, newUUId); $(el).attr("href", newHref); }); }); An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing. Browse Gateways Collections How it Works Contact For Developers Cookie Notice Privacy Notice RSS Submit Your Research Follow us © 2012-2026 F1000 Research Ltd. ISSN 2046-1402 | Legal | Partner of Research4Life • CrossRef • ORCID • FAIRSharing R.templateTests.simpleTemplate = R.template(' $text $text $text $text $text '); R.templateTests.runTests(); var F1000platform = new F1000.Platform({ name: "f1000research", displayName: "F1000Research", hostName: "f1000research.com", id: "1", editorialEmail: "[email protected]", infoEmail: "[email protected]", usePmcStats: true }); $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');}); // $(function(){R.ui.dropdowns('.dropdown-for-referees');}); $(document).ready(function () { if ($(".cookie-warning").is(":visible")) { $(".sticky").css("margin-bottom", "35px"); $(".devices").addClass("devices-and-cookie-warning"); } $(".cookie-warning .close-button").click(function (e) { $(".devices").removeClass("devices-and-cookie-warning"); $(".sticky").css("margin-bottom", "0"); }); $("#tweeter-feed .tweet-message").each(function (i, message) { var self = $(message); self.html(linkify(self.html())); }); $(".partner").on("mouseenter mouseleave", function() { $(this).find(".gray-scale, .colour").toggleClass("is-hidden"); }); }); Sign In Remember me Forgotten your password? Sign In Cancel Email or password not correct. Please try again Please wait... $(function(){ // Note: All the setup needs to run against a name attribute and *not* the id due the clonish // nature of facebox... $("a[id=googleSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("GOOGLE"); $("form[id=oAuthForm]").submit(); }); $("a[id=facebookSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("FACEBOOK"); $("form[id=oAuthForm]").submit(); }); $("a[id=orcidSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("ORCID"); $("form[id=oAuthForm]").submit(); }); }); If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password. The email address should be the one you originally registered with F1000. Email address not valid, please try again You registered with F1000 via Google, so we cannot reset your password. To sign in, please click here . If you still need help with your Google account password, please click here . You registered with F1000 via Facebook, so we cannot reset your password. To sign in, please click here . If you still need help with your Facebook account password, please click here . Code not correct, please try again Reset password Cancel Email us for further assistance. Server error, please try again. If your email address is registered with us, we will email you instructions to reset your password. If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance. Please wait... Register $(document).ready(function () { signIn.createSignInAsRow($("#sign-in-form-gfb-popup")); $(".target-field").each(function () { var uris = $(this).val().split("/"); if (uris.pop() === "login") { $(this).val(uris.toString().replace(",","/")); } }); });